Check for updates

OPEN ACCESS

EDITED BY John Gibbs, Hackensack Meridian Health, United States

REVIEWED BY Francesca Marcon, IRCCS Ca 'Granda Foundation Maggiore Policlinico Hospital, Italy Heba Taher, Cairo University, Egypt Tevfiktolga Sahin, Ínönü University, Türkiye

*CORRESPONDENCE Yanhua Sha Shayanhua2013@163.com Bailin Wang wangbailin888@sina.com

SPECIALTY SECTION

This article was submitted to Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers, a section of the journal Frontiers in Oncology

RECEIVED 09 November 2022 ACCEPTED 30 December 2022 PUBLISHED 25 January 2023

CITATION

Yan Y, Hua Y, Chang C, Zhu X, Sha Y and Wang B (2023) Laparoscopic versus open pancreaticoduodenectomy for pancreatic and periampullary tumor: A meta-analysis of randomized controlled trials and nonrandomized comparative studies. *Front. Oncol.* 12:1093395. doi: 10.3389/fonc.2022.1093395

COPYRIGHT

© 2023 Yan, Hua, Chang, Zhu, Sha and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Laparoscopic versus open pancreaticoduodenectomy for pancreatic and periampullary tumor: A meta-analysis of randomized controlled trials and non-randomized comparative studies

Yong Yan¹, Yinggang Hua¹, Cheng Chang¹, Xuanjin Zhu¹, Yanhua Sha^{2*} and Bailin Wang^{1*}

¹Department of General Surgery, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China, ²Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

Objective: This meta-analysis compares the perioperative outcomes of laparoscopic pancreaticoduodenectomy (LPD) to those of open pancreaticoduodenectomy (OPD) for pancreatic and periampullary tumors.

Background: LPD has been increasingly applied in the treatment of pancreatic and periampullary tumors. However, the perioperative outcomes of LPD versus OPD are still controversial.

Methods: PubMed, Web of Science, EMBASE, and the Cochrane Library were searched to identify randomized controlled trials (RCTs) and non-randomized comparative trials (NRCTs) comparing LPD versus OPD for pancreatic and periampullary tumors. The main outcomes were mortality, morbidity, serious complications, and hospital stay. The secondary outcomes were operative time, blood loss, transfusion, postoperative pancreatic fistula (POPF), postpancreatectomy hemorrhage (PPH), bile leak (BL), delayed gastric emptying (DGE), lymph nodes harvested, R0 resection, reoperation, and readmission. RCTs were evaluated by the Cochrane risk-of-bias tool. NRCTs were assessed using a modified tool from the Methodological Index for Non-randomized Studies. Data were pooled as odds ratio (OR) or mean difference (MD). This study was registered at PROSPERO (CRD42022338832).

Results: Four RCTs and 35 NRCTs concerning a total of 40,230 patients (4,262 LPD and 35,968 OPD) were included. Meta-analyses showed no significant differences in mortality (OR 0.91, p = 0.35), serious complications (OR 0.97, p = 0.74), POPF (OR 0.93, p = 0.29), PPH (OR 1.10, p = 0.42), BL (OR 1.28, p = 0.22), harvested lymph nodes (MD 0.66, p = 0.09), reoperation (OR 1.10, p = 0.41), and readmission (OR 0.95, p = 0.46) between LPD and OPD. Operative time was significantly longer for LPD (MD 85.59 min, p < 0.00001), whereas overall morbidity (OR 0.80, p < 0.00001), hospital stay (MD –2.32 days, p < 0.00001), blood loss (MD –173.84 ml,

p < 0.00001), transfusion (OR 0.62, p = 0.0002), and DGE (OR 0.78, p = 0.002) were reduced for LPD. The R0 rate was higher for LPD (OR 1.25, p = 0.001).

Conclusions: LPD is associated with non-inferior short-term surgical outcomes and oncologic adequacy compared to OPD when performed by experienced surgeons at large centers. LPD may result in reduced overall morbidity, blood loss, transfusion, and DGE, but longer operative time. Further RCTs should address the potential advantages of LPD over OPD.

Systematic review registration: PROSPERO, identifier CRD42022338832.

KEYWORDS

laparoscopic pancreaticoduodenectomy, open pancreaticoduodenectomy, whipple, pancreatic head, periampullary tumor, meta-analysis

Introduction

Pancreaticoduodenectomy (PD) is the standard surgical treatment for pancreatic and periampullary tumors, which involves resection of the duodenum as well as with or without the distal stomach, the first portion of the jejunum, the pancreatic head, and common bile duct with the gallbladder (1). Owing to the complicated operation process and potentially lethal complications, PD should be performed by proficient surgeons in high-volume centers (2). Despite improved proficiency and technique, the perioperative mortality rate of PD remains up to 3% in highly specialized centers (3). PD remains the most difficult procedure of abdominal surgery and is associated with a high risk of morbidity and mortality (4).

The advantage of minimal invasiveness, reduced pain, and fast recovery from laparoscopic surgery has made it become the standard procedure in appendectomy and cholecystectomy (5, 6). With the accumulation of laparoscopic surgical experience and the development of surgical instruments, laparoscopic surgery has also been widely used in complex procedures such as gastrectomy, colectomy, and rectectomy, and it has been proven to be safe and feasible as compared with the open approach (7–9). During the past decades, there has been an increasing effort to perform more complex procedures like PD with a laparoscopic approach. However, a laparoscopic procedure in such complex conditions often arouses concerns with the difficult maneuvering of vascular structures, complicated digestive tract reconstruction, and prolonged operative time.

Laparoscopic pancreatoduodenectomy (LPD) was first reported in Canada in 1994 by Gagner et al., where it was performed with a pylorus-preserving procedure for a patient with chronic pancreatitis (10). In the initial stage, most surgeons choose to carry out LPD for patients with benign diseases. Due to improvements in surgical technique, LPD has been increasingly applied in the treatment of pancreatic and periampullary tumors, regardless of their benign or malignant nature (3). In recent years, a series of cohort studies have demonstrated the technical feasibility and safety of LPD for pancreatic and periampullary tumors (11, 12). However, the effects of LPD versus open pancreaticoduodenectomy (OPD) on morbidity, oncologic adequacy, and mortality are still controversial (13). Despite that there were several meta-analyses that assessed surgical and oncologic outcomes between LPD and OPD in the past 5 years (14–19), which included few articles and patients, and there had been conflicting pooled results. Some have included a few available randomized controlled trials (RCTs), which could not show any significant differences (14–16). Furthermore, some meta-analyses included studies that reported overlapped data from the same database during the crossed time period and therefore were prone to bias (17, 19–21). There is evidence that pooling of high-quality non-randomized comparative trials (NRCTs) is appropriate in a meta-analysis comparing surgical procedures, as existing RCTs are few, have a small sample size, and are underpowered (22).

This meta-analysis aims to assess the potential advantage of LPD compared with OPD for pancreatic and periampullary tumors using all the available high-quality published trials, RCTs and NRCTs, while focusing on perioperative outcomes such as mortality, morbidity, hospital stay, operative time, blood loss, transfusion, oncologic adequacy, reoperation, and readmission.

Methods

This meta-analysis followed the Cochrane Handbook for Systematic Reviews of Interventions, as well as Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations (23, 24). This study was registered at PROSPERO (CRD42022338832).

Search strategy

We searched the English-language literature published up to May 2022 in PubMed, Web of Science, EMBASE, and the Cochrane Library. The search terms were as follows: [laparoscopic OR laparoscopy OR laparoscopically assisted OR minimally invasive OR minimal invasive surgery] AND [open OR conventional OR open conventional surgery] AND [pancreatoduodenectomy OR pancreaticoduodenectomy OR Pancreatectomy OR Whipple] AND [randomized controlled trial OR prospective study OR comparative study OR retrospective study]. Two authors (Yong Yan and Yinggang Hua) independently conducted the literature search and a cross-check.

Inclusion and exclusion criteria

Two authors (Yong Yan and Yinggang Hua) screened eligible articles independently according to the inclusion criteria: 1) the interventions compared included LPD versus OPD, 2) elective PD for pancreatic or periampullary tumor, 3) adult patients, and 4) reported perioperative outcomes. The exclusion criteria were as follows: 1) experimental or animal studies, 2) single surgical technique with no comparative data, 3) studies without perioperative data, 4) emergency PD for abdominal trauma, and 5) the publication type was editorial, abstract, letter, case report, and expert opinion. If papers had overlapping data, the latest studies with the biggest sample size were included.

Data extraction

The data were extracted using a predefined data extraction sheet. Both authors (Yong Yan and Yinggang Hua) independently extracted data and then cross-checked them. In case of inconsistencies, a third author (Cheng Chang) was consulted to reach a consensus. Parameters such as study characteristics, demographic characteristics, baseline characteristics, baseline matching, methodological quality, inclusion diseases, surgical details, surgeons' experience, and open conversion were extracted. The primary outcomes were postoperative mortality, overall postoperative complications, severe postoperative complications, and length of hospital stay. Furthermore, the secondary outcomes comprised operative time, estimated blood loss, intraoperative blood transfusion, pancreas-specific complications (such as postoperative pancreatic fistula (POPF), postpancreatectomy hemorrhage (PPH), bile leak (BL), and delayed gastric emptying (DGE)), oncologic outcomes (such as harvested lymph nodes and R0 resection), reoperation, and unplanned readmission.

Quality assessment

The Cochrane risk-of-bias tool was used for assessing the methodological quality of all included RCTs (25). The Methodological Index for Non-randomized Studies (MINORS) is an instrument that was developed by a group of practicing surgeons in France and validated specifically for NRCT evaluation (26). In this meta-analysis, a modified scale from a previously published meta-analysis on a similar surgical comparison was adopted (27). In this modified MINORS score, four items were not included because they mainly evaluate the reporting quality and the validity of long-term outcomes. The score of sample size was assessed by the actual number of LPD cases, as follows: 0 points for less than 20 LPD cases, 1 point for 20 or more but less than 50 cases, and 2 points for 50 or more LPD

cases. In total, eight items were evaluated, with a maximum score of 16 points. Studies with 12 or more points were considered high quality.

Statistical analysis

Review Manager 5.4 was used to analyze the data. RCTs and NRCTs were first analyzed separately and then combined using a stratified analysis. For dichotomous data, the odds ratio (OR) with a 95% confidence interval (CI) was calculated. For continuous data, the mean difference (MD) with 95% CI was calculated. The median and range were converted to mean and standard deviation by using mathematical models of Hozo et al. (28), and the mean and standard deviation from the sample size, median, and interquartile range were estimated using mathematical models by Wan et al. (29) Heterogeneity was assessed by I^2 , with values of 50% or more indicating significant heterogeneity. The random-effects model was used when I^2 was 50% or more, and the fixed-effects model was used when I^2 was less than 50%. p < 0.05 was statistically significant. Subgroup analysis and estimation of publication bias were also performed. Subgroup analysis was planned for studies of all malignancies, benign and malignant, LPD cases of 50 or less, LPD cases of more than 50, baseline matching incomplete, and baseline matching complete.

Results

Study selection

The flow diagram of the study selection procedure is shown in Supplementary Figure 1. The titles and abstracts of 1,651 studies were screened for inclusion. Of these, 1,591 were excluded due to ineligibility. The full texts of 60 studies were screened, of which three studies (30–32) presented patients from the National Cancer Database (NCDB) and two studies (33, 34) presented patients from the National Surgical Quality Improvement Program (NSQIP) with overlapped study intervals, and the latest studies (32, 34) with the biggest sample size were included. After assessment according to selection criteria and excluding overlapped studies, 39 studies published between 2012 and 2022 included in the quantitative synthesis were identified. These included 4 RCTs (35–38) and 35 NRCTs (32, 34, 39–71).

Quality assessment

The summarized risk-of-bias assessment for RCTs is presented in Supplementary Figure 2. The random sequence generation was adequate in all RCTs. As the RCT of Poves et al. (36) did not specify the method of allocation concealment, it received an unclear risk-of-bias score. All included RCTs had a high risk of bias for blinding, except the RCT of van Hilst et al. (37) received a low risk-ofbias score for patient blinding by using a large abdominal dressing. All included RCTs had a low risk of attrition and reporting bias, but received a high risk of other bias, as the surgeons might not reach proficiency in three RCTs (35–37) and high cross-over in both groups might affect outcomes in RCT of Wang et al. (38) Assessment of NRCTs is displayed in Supplementary Table 1. The median score was 12 points. A total of 24 NRCTs with 12 or more points were considered high quality, whereas the remaining 11 NRCTs had scores between 10 and 11.

Study characteristics

The major characteristics of included studies are summarized in Table 1. Four included RCTs were published after 2016 and carried out between 2013 and 2019 in four different countries (India, Spain, the Netherlands, and China). Two of the RCTs were multicentric studies (37, 38). The RCT of Palanivelu et al. (35) only included patients with periampullary cancers, while the other three RCTs (36–

TABLE 1 Study characteristics.

38) included patients with benign, premalignant, or malignant conditions. All RCTs were adequately matched in reviewed baseline characteristics. Of the 35 included NRCTs, 25 were conducted in three countries (10 in the USA, 8 in China, and 7 in South Korea). The study periods of included NRCTs mostly were between 2010 and 2020 (range 1993 to 2020), and 23 NRCTs were published between 2017 and 2022. All included NRCTs were retrospective studies, 15 of which were designed using propensity score matching analysis. A total of 18 NRCTs only included patients with malignant conditions, while the other 17 NRCTs included patients with benign, premalignant, and malignant conditions. The reported conversion rates in each included study varied between 3.1% and 24.1%.

The baseline characteristics of patients in each treatment group are summarized in Table 2. A total of 40,230 patients were included in the analysis with 4,262 (10.6%) having undergone LPD and 35,968 (89.4%) having undergone OPD, and 23,186 (57.6%) were women.

Study	Country	Study period	Study design	Included diseases	Conversion (%)	Matched factors	Not matched
Palanivelu 2017 (35)	India	2013-2015	Single-center, open-label, RCT	Periampullary cancers	3.1	1, 2, 3, 4, 5, 6, 7, 8	_
Poves 2018 (36)	Spain	2013-2017	Single-center, open-label, RCT	Benign, premalignant, malignant	23.5	1, 2, 3, 4, 5, 6, 7, 8	_
van Hilst 2019 (37)	Netherlands	2016-2017	Multicenter, patient- blinded, RCT	Benign, premalignant, malignant	20	1, 2, 3, 4, 5, 6, 7, 8	_
Wang M 2021 (38)	China	2018-2019	Multicenter, open-label, RCT	Benign, premalignant, malignant	3.7	1, 2, 3, 4, 5, 6, 7, 8	_
Ammori 2020 (39)	Jordan	2015-2018	Retrospective, PS	Benign or malignant	-	1, 2, 3, 6, 7, 8	_
Asbun 2012 (40)	USA	2005-2011	Retrospective, database	Benign, premalignant, malignant	_	1, 2, 3, 4, 5, 6, 7, 8	_
Chen K 2021 (41)	China	2004-2020	Retrospective, database, PS	Pancreatic ductal adenocarcinoma	9.9	1, 2, 3, 4, 5, 7, 8	-
Chen XM 2018 (42)	China	2013-2017	Retrospective	Periampullary malignancy	_	1, 2, 3, 4, 5, 7, 8	_
Choi 2020 (43)	South Korea	2014-2019	Retrospective	Pancreatic head cancer	_	1, 2, 3, 4, 6, 7, 8	_
Chopinet 2018 (44)	France	2002-2014	Retrospective	Periampullary tumors	9.2	1, 2, 3, 5, 7	4
Conrad 2017 (45)	USA	2000-2010	Retrospective, database	Periampullary or pancreatic head adenocarcinoma	_	1, 2, 3, 4, 7, 8	-
Croome 2014 (46)	USA	2008-2013	Retrospective, database	Pancreatic ductal adenocarcinoma	6.5	1, 3, 5, 7, 8	2
Dang C 2021 (47)	China	2011-2019	Retrospective, PS	Non-pancreatic periampullary adenocarcinoma	_	1, 2, 3, 5, 7, 8	_
Delitto 2016 (48)	USA	2010-2014	Retrospective, database	Periampullary malignancy	9.1	1, 2, 3, 5, 7	8
Ding W 2021 (49)	China	2015-2020	Retrospective, PS	Benign or malignant	_	1, 2, 3, 5, 7, 8	_
Dokmak 2014 (50)	France	2011-2014	Retrospective, database	Periampullary tumors	6.5	1, 2, 5, 7, 8	3
El Nakeeb 2020 (51)	Egypt	2013-2018	Retrospective, PS	Periampullary tumors	10.8	1, 2, 3, 5, 8	_

TABLE 1 Continued

Study	Country	Study period	Study design	Included diseases	Conversion (%)	Matched factors	Not matched
Han SH 2020 (52)	South Korea	2012-2017	Retrospective, PS	Benign, premalignant, malignant	-	1, 2, 3, 4, 5, 6, 8	-
Kantor 2017 (32)	USA	2010-2013	Retrospective, NCDB	Pancreatic adenocarcinoma		1, 7	-
Katsuki 2021 (53)	Japan	2016-2018	Retrospective, database	Benign or borderline tumors	_	1, 2, 5, 7	-
Khaled 2018 (54)	UK	2002-2015	Retrospective, PS	Malignant tumors	6.7	1, 2, 3, 4, 7, 8	-
Kuesters 2018 (55)	Germany	2010-2016	Retrospective, database	Pancreatic ductal adenocarcinoma	-	1, 2, 3, 7, 8	_
Lee CS 2018 (56)	South Korea	1993–2017	Retrospective, PS	Benign or borderline malignant	-	1, 2, 3, 4, 7, 8	_
Mazzola 2021 (57)	Italy	2013-2020	Retrospective, PS	Benign, premalignant, malignant	3.8	1, 2, 3, 4, 5, 7	-
Mendoza 2015 (58)	South Korea	2014	Retrospective	Periampullary tumors	-	1, 2, 3, 4, 5, 6, 8	-
Meng LW 2018 (59)	China	2010-2015	Retrospective, database	Non-pancreatic periampullary adenocarcinoma	-	1, 2, 3, 4, 5, 7, 8	-
Mesleh 2013 (60)	USA	2009-2012	Retrospective	Benign, premalignant, malignant	4	2, 3, 4, 7	-
Senthilnathan 2015 (61)	India	2006-2011	Retrospective, database	Periampullary and pancreatic head malignancy	-	1, 2, 3, 7, 8	-
Shin 2019 (62)	South Korea	2014-2017	Retrospective, PS	Periampullary malignancy	-	1, 2, 3, 4, 7, 8	-
Song KB 2015 (63)	South Korea	2007-2012	Retrospective, PS	Benign or low-grade malignant	-	1, 2, 3, 5, 6, 7, 8	
Stauffler 2016 (64)	USA	1995-2014	Retrospective, database	Pancreatic ductal adenocarcinoma	24.1	1, 2, 3, 5, 7	8
Tan CL 2015 (65)	China	2009-2014	Retrospective, database	Benign, premalignant, malignant	-	1, 2, 4, 5, 7	-
Tan JKH 2019 (66)	Singapore	2014-2016	Retrospective, PS	Malignant tumors	5	1, 2, 5, 8	
Tee MC 2015 (67)	USA	2007-2014	Retrospective, database	Benign, premalignant, malignant	-	1, 3, 5, 6, 7	2
Tran 2016 (68)	USA	2000-2010	Retrospective, NIS	Benign, premalignant, malignant	-	2, 5	1
Xourafas 2018 (34)	USA	2014-2016	Retrospective, NSQIP	Benign, premalignant, malignant	21	1, 2, 3, 4	5, 7
Yoo 2020 (69)	South Korea	2011-2017	Retrospective, PS	Ampulla of Vater cancer	-	1, 2, 3, 4, 5, 7, 8	-
Zhang Z 2022 (70)	China	2014-2018	Retrospective, PS	Pancreatic ductal adenocarcinoma	4.3	1, 2, 3, 4, 5, 6, 7, 8	_
Zhou W 2019 (71)	China	2013-2017	Retrospective, PS	Pancreatic ductal adenocarcinoma	_	1, 2, 3, 4, 5, 7	_

Matching factors: 1, age; 2, gender; 3, BMI; 4, ASA score; 5, comorbidities; 6, classic/pylorus-preserving PD; 7, malignancy rate; 8, tumor size.

BMI, body mass index; RCT, randomized controlled trial; PS, propensity score matching; ASA, American Society of Anesthesiologists; PD, pancreaticoduodenectomy; NCDB, National Cancer Database; NSQIP, National Surgical Quality Improvement Program; NIS, Nationwide Inpatient Sample.

Among them, 818 (2.0%) cases were from the four included RCTs, 411 (9.6% of all LPD cases) of which were in the LPD group and 407 in the OPD group (1.1% of all OPD cases). However, in 17 studies, 14 NRCTs and 3 RCTs had LPD cases of no more than 50. The mean/ median age and body mass index (BMI) in each treatment group ranged from 49.6 to 76.5 years and 21.3 to 28.7 kg/m², respectively.

The overall comorbidity rates reported in each treatment group were between 37.6% and 61.2%. The most common comorbidities, diabetes mellitus (DM) and hypertension (HTN), ranged from 3.0% to 44.0% and 10.0% to 69.0%, respectively. The malignancy rate ranged from 66.4% to 97.3% in studies not specific to malignant conditions. The mean/median size of the tumor ranged from 1.8 to 3.6 cm.

TABLE 2 Demographic and baseline characteristics of patients in included studies.

Study	Procedure	Cases	Age (years)	No. (M/ F)	BMI (kg/ m ²)	ASA I/II/III	Comorbidities, n (%)	Classic/pylorus- preserving PD	Malignancy, n (%)	Tumor size (cm)
Palanivelu 2017 (35)	LPD	32	57.8 ± 2.0	18/14	24.9 ± 0.7	13/17/2	15 (46.9)	10/22	32 (100)	3.3 ± 0.7
	OPD	32	58.6 ± 2.1	22/10	22.4 ± 0.6	11/18/3	17 (53.1)	6/26	32 (100)	3.6 ± 1.9
Poves 2018 (36)	LPD	32	69 (34– 86) ^e	13/19	24 (16– 33) ^e	1/18/13	5 (0-8) ^k	6/25	24 (75.0)	2.4 (0.9– 7.0) ^b
	OPD	29	70 (36– 83) ^e	20/9	26 (17– 43) ^e	1/13/15	5 (1–10) ^k	11/18	25 (86.2)	2.9 (1.2– 7.5) ^b
van Hilst 2019 (37)	LPD	50	67 (59– 76) ^a	20/30	25 ± 3	5/32/13	DM 6 (12)	8/38	44 (80.0)	2.6 ± 14
	OPD	49	66 (61– 73) ^a	25/24	26 ± 4	7/26/16	DM 10 (20)	8/39	43 (87.8)	2.6 ± 12
Wang M 2021 (38)	LPD	297	61 (54– 67) ^a	171/ 126	22.4 ± 2.9	51/177/ 69	121 (41)	242/55	229 (77.1)	2.4 ± 0.7
	OPD	297	60 (52– 66) ^a	193/ 104	22.1 ± 3.1	50/191/ 56	133 (45)	254/43	232 (78.1)	2.5 ± 0.9
Ammori 2020 (39)	LPD	11	57 (48– 72) ^b	5/6	25.0 (17.0– 44.9) ^b	-	_	11/0	9 (81.8)	3 (0-5) ^b
	OPD	22	63 (22– 75) ^b	12/10	28.7 (15.5– 39.4) ^b	-	_	14/8	18 (81.8)	3 (0-7.5) ^b
Asbun 2012 (40)	LPD	53	62.9 ± 14.14	29/24	27.64 ± 7.16	13/39/ 1 ^f	DM 14 (26.4); HTN 30 (56.6)	3/39	51 (96.2)	2.74 ± 1.6
	OPD	215	67.3 ± 11.53	95/ 120	26.6 ± 5.08	37/163/ 13 ^f	DM 60 (27.9); HTN 130 (60.5)	70/98	195 (90.6)	3.14 ± 1.5
Chen K 2021 (41)	LPD	101	62.4 ± 8.2	67/34	22.3 ± 2.5	47/52/2	44 (43.5)	_	101 (100)	3.0 ± 0.9
	OPD	101	62.2 ± 8.4	67/34	22.5 ± 2.6	45/54/2	46 (45.5)	-	101 (100)	3.1 ± 1.0
Chen XM 2018 (42)	LPD	47	63 ± 12	26/21	24 ± 3	1.5 ± 1 ^g	DM 14 (29.8); HTN 14 (29.8)	_	47 (100)	2.5 ± 1.5
	OPD	55	66 ± 15	34/21	22.7 ± 3.3	1.5 ± 1 ^g	DM 20 (36.3); HTN 18 (32.7)	-	55 (100)	3.0 ± 1.8
Choi 2020 (43)	LPD	27	63.3 ± 9.4	12/15	23.2 ± 2.1	2/12/13	-	0/27	27 (100)	2.8 ± 1.0
	OPD	34	63.3 ± 9.4	18/16	22.9 ± 3.4	2/16/16	-	0/34	34 (100)	2.9 ± 1.3
Chopinet 2018 (44)	LPD	65	62.6 (31–83) ^b	39/26	23 (15– 35) ^b	52 (82) ^h	DM 13 (20); HTN 22 (34)	-	51 (78.5)	-
	OPD	290	62.7 (19–84) ^b	165/ 125	23 (17– 38) ^b	210 (72) ^h	DM 45 (16); HTN 88 (30)	_	237 (81.7)	_
Conrad 2017 (45)	LPD	40	68 (45– 83) ^b	26/14	23.9 (14.8– 34.1) ^b	2 (1-3) ⁱ	_	_	40 (100)	2.5 (0.3– 8.0) ^b
	OPD	25	66 (43– 76) ^b	18/7	24.5 (20.7– 31.1) ^b	2 (1-4) ⁱ	_	_	25 (100)	3.0 (1.3– 6.0) ^b
Croome 2014 (46)	LPD	108	66.6 ± 9.6	51/57	27.4 ± 5.4	-	DM 33 (30.6); HTN 54 (50.0)	_	108 (100)	3.3 ± 1.0

TABLE 2 Continued

Study	Procedure	Cases	Age (years)	No. (M/ F)	BMI (kg/ m ²)	ASA I/II/III	Comorbidities, n (%)	Classic/pylorus- preserving PD	Malignancy, n (%)	Tumor size (cm)
	OPD	214	65.4 ± 10.9	131/ 83	27.2 ± 5.3	-	DM 67 (31.3); HTN 91 (42.5)	_	214 (100)	3.3 ± 1.3
Dang C 2021 (47)	LPD	131	57.4 ± 9.4	79/52	21.7 ± 2.8	-	DM 6 (4.5)	_	131 (100)	1.7 (1.3– 2.5) ^a
	OPD	131	57.5 ± 9.5	81/50	21.6 ± 2.9	-	DM 4 (3.0)	_	131 (100)	1.7 (1.3– 2.8) ^a
Delitto 2016 (48)	LPD	52	65.3 ^c	34/18	26.3 ^c	_	5.8 ¹	-	52 (100)	2.5 ^c
	OPD	50	68.6 ^c	28/22	25.5 ^c	-	6.0 ¹	-	50 (100)	3.1 ^c
Ding W 2021 (49)	LPD	112	66.0 ± 9.2	60/52	22.9 ± 2.7	-	DM 12 (10.7); HTN 35 (31.3)	-	84 (75.0)	2.9 ± 1.5
	OPD	112	64.1 ± 10.6	65/47	22.1 ± 3.9	_	DM 19 (20.0); HTN 32 (28.6)	-	90 (80.3)	3.2 ± 1.7
Dokmak 2015 (50)	LPD	46	60 (27– 85) ^b	26/20	22.6 (17-30) ^b	_	DM 12 (26); HTN 11 (24)	-	36 (78.3)	2.82 (1.2- 4) ^b
	OPD	46	63 (47– 81) ^b	28/18	26.4 (19–42) ^b	-	DM 17 (39); HTN 17 (37)	-	36 (78.3)	2.51 (1.5- 4) ^b
El Nakeeb 2020 (51)	LPD	37	54 (33– 62) ^b	22/15	-	_	DM 11 (29.7); HTN 9 (24.3)	-	33 (89.2)	3 (1-4) ^b
	OPD	74	53 (17– 63) ^b	40/34	-	-	DM 25 (33.8); HTN 17 (23)	-	62 (83.8)	3 (1-6) ^b
Han SH 2020 (52)	LPD	104	61.5 ± 12.0	53/51	23.57 ± 2.72	9/57/38	DM 33 (31.7); HTN 37 (35.6)	0/104	_	2.5 ± 1.3
	OPD	113	64.5 ± 9.2	70/43	23.22 ± 3.09	5/55/53	DM 42 (37.2); HTN 49 (43.4)	0/113	-	2.7 ± 1.2
Kantor 2017 (32)	LPD	828	65.9 ± 10.7	-	-	-	-	-	828 (100)	-
	OPD	7,385	65.7 ± 10.4	-	-	-	-	-	7,385 (100)	-
Katsuki 2021 (53)	LPD	95	61 (51– 72) ^a	49/46	-	_	DM 42 (44); HTN 57 (60)	_	-	-
	OPD	380	63 (56– 73) ^a	193/ 187	-	-	DM 167 (44); HTN 239 (63)	-	-	-
Khaled 2018 (54)	LPD	15	65 (35– 78) ^b	8/7	23.4 (18-26) ^b	15 (100) ^h	_	_	15 (100)	2.0 (0.7– 8.0) ^b
	OPD	15	64.3 (45-76) ^b	8/7	24.9 (22-28) ^b	15 (100) ^h	_	_	15 (100)	2.2 (1.5– 7.8) ^b
Kuesters 2018 (55)	LPD	62	71 ^d	31/31	24.7 (15-39) ^b	_	_	-	62 (100)	2.8 (0.1– 7.5) ^b
	OPD	278	68 ^d	137/ 141	24.7 (16-46) ^b	_	_	_	278 (100)	2.7 (0.3– 13.0) ^b
Lee CS 2018 (56)	LPD	31	56.4 ± 14.6	14/17	24.0 ± 3.3	13/13/5	_	_	-	3.3 ± 2.1
	OPD	31	58.0 ± 11.4	13/18	23.8 ± 2.7	2,015/ 11/5	_	-	-	3.3 ± 2.3
Mazzola 2021 (57)	LPD	50	67.5 (61–75) ^a	25/25	25 (23– 28) ^a	5/41/4	5 (4–5) ^m	_	44 (88)	-
	OPD	50	71 (65– 76) ^a	25/25	25.5 (22–28) ^a	4/38/8	5 (4-6) ^m	-	44 (88)	-

TABLE 2 Continued

Study	Procedure	Cases	Age (years)	No. (M/ F)	BMI (kg/ m²)	ASA I/II/III	Comorbidities, n (%)	Classic/pylorus- preserving PD	Malignancy, n (%)	Tumor size (cm)
Mendoza 2015 (58)	LPD	18	63.7 ± 10.9	10/8	22.7 ± 3.1	18 (100) ^h	0.8 (0-2) ^m	2/16	-	2.9 ± 0.9
	OPD	34	68.4 ± 7.6	21/13	21.9 ± 3.0	29 (85.3) ^h	1.0 (0-3) ^m	11/23	-	3.1 ± 2.9
Meng LW 2018 (59)	LPD	58	59.9 ± 9.1	32/26	22.2 ± 2.9	28/30 ^j	DM 4 (6.9); HTN 9 (15.5)	_	58 (100)	1.8 (1.5– 2.6) ^a
	OPD	58	60.3 ± 8.6	34/24	22.9 ± 2.3	34/24 ^j	DM 6 (10.3); HTN 6 (10.3)	_	58 (100)	2.0 (1.9– 3.0) ^a
Mesleh 2013 (60)	LPD	75	-	43/32	_	-	_	_	73 (97.3)	-
	OPD	48	-	23/25	-	-	_	_	42 (87.5)	-
Senthilnathan 2015 (61)	LPD	45	54 ± 11.6	17/28	27.6 ^c	-	_	-	45 (100)	2.8 ^c
	OPD	118	56 ± 10.8	59/59	28.1 ^c	-	-	-	118 (100)	3.1 ^c
Shin 2019 (62)	LPD	56	74.8 ± 3.7	27/29	22.8 ± 2.6	2.1 ± 0.5	_	_	56 (100)	2.7 ± 1.2
	OPD	56	74.7 ± 3.5	25/31	22.6 ± 2.3	2.1 ± 0.4	_	_	56 (100)	2.6 ± 1.2
Song KB 2015 (63)	LPD	93	49.6 ± 13.4	47/46	22.8 ± 2.7	-	1.6 (0-3) ^m	0/93	_	3.1 ± 1.4
	OPD	93	50.1 ± 13	47/46	23.1 ± 2.5	-	1.5 (0-3) ^m	0/93	-	3.4 ± 2.1
Stauffler 2016 (64)	LPD	58	69.9 (40.6– 84.8) ^b	32/26	25.9 (17.7– 49.6) ^b	_	DM 19 (32.8); HTN 33 (56.9)	_	53 (100)	2.5 (0.3– 10.0) ^b
	OPD	193	68.9 (33.3– 86.9) ^b	96/97	25.6 (15.0– 46.1) ^b	-	DM 62 (32.1); HTN 128 (66.3)	-	198 (100)	3.5 (0.3– 14.0) ^b
Tan CL 2015 (65)	LPD	30	59.3 ± 9.3	18/12	_	6/19/5	DM 3 (10.0); HTN 3 (10.0)	-	27 (90.0)	_
	OPD	30	59.9 ± 10.4	23/7	-	6/18/6	DM 2 (6.7); HTN 4 (13.3)	_	26 (86.7)	-
Tan JKH 2019 (66)	LPD	20	65 (37– 82) ^b	11/9	_	-	12/7/1 ⁿ	_	20 (100)	2.1 (1.0- 3.5) ^b
	OPD	20	64 (46- 84) ^b	11/9	_	-	12/6/2 ⁿ	-	20 (100)	2.0 (1.0- 4.0) ^b
Tee MC 2015 (67)	LPD	113	76.5 ± 4.3	51/62	26.9 ± 4.7	-	DM 29 (25.7); HTN 78 (69.0)	100/13	75 (66.4)	-
	OPD	225	76.4 ± 4.5	140/ 85	26.8 ± 4.3	_	DM 73 (32.4); HTN 154 (68.4)	195/30	192 (85.3)	-
Tran 2016 (68)	LPD	681	67 (58– 73) ^a	377/ 304	_	_	417 (61.2)	_	-	-
	OPD	14,893	65 (56– 73) ^a	7,701/ 7,192	_	_	8,744 (58.7)	_	-	-
Xourafas 2018 (34)	LPD	418	63 (19– 87) ^a	233/ 185	27.6 (16–67) ^a	1/104/ 296	DM 94 (22); HTN 192 (46)	_	319 (76.3)	-
	OPD	9,963	65 (18– 89) ^a	5,359/ 4,604	27.2 (15–69) ^a	37/ 2,239/ 7,006	DM 2,525 (25); HTN 5,305 (53)	-	8,020 (80.5)	-

TABLE 2 Continued

Study	Procedure	Cases	Age (years)	No. (M/ F)	BMI (kg/ m²)	ASA I/II/III	Comorbidities, n (%)	Classic/pylorus- preserving PD	Malignancy, n (%)	Tumor size (cm)
Yoo 2020 (69)	LPD	69	62.8 ± 10.1	34/35	23.1 ± 2.7	5/56/8	2.2 ± 1.3^{l}	_	69 (100)	1.9 ± 1.0
	OPD	69	63.2 ± 8.6	38/31	23.5 ± 3.3	7/55/7	2.3 ± 1.1^{1}	-	69 (100)	1.8 ± 1.0
Zhang Z 2022 (70)	LPD	47	57.6 ± 8.3	31/16	21.3 ± 2.2	42 (89.4) ^h	DM 2 (4.3); HTN 6 (12.8)	47/0	47 (100)	2.6 ± 0.8
	OPD	47	57.5 ± 8.7	30/17	21.4 ± 2.6	41 (87.2) ^h	DM 3 (6.4); HTN 7 (14.9)	47/0	47 (100)	2.7 ± 1.0
Zhou W 2019 (71)	LPD	55	63 (54– 69) ^a	40/15	23.0 (20.7– 25.2) ^a	5/47/3	24 (43.6)	_	55 (100)	-
	OPD	93	64 (59– 70.5) ^a	68/25	22.3 (20.3– 23.9) ^a	18/73/2	35 (37.6)	-	93 (100)	-

LPD, laparoscopic pancreaticoduodenectomy; OPD, open pancreaticoduodenectomy; PD, pancreaticoduodenectomy; No. (M/F), number of patients (male/female); BMI, body mass index; ASA, American Society of Anesthesiologists; IQR, interquartile range; CCI, Charlson Comorbidity Index; DM, diabetes mellitus; HTN, hypertension.

^aMedian (IQR). ^bMedian (range). ^cMean. ^dMedian. ^cMean (range). ^fASA II/III/IV. ^gMean ± SD of ASA score. ^hNumber (%) of ASA score ≤II. ⁱMedian (range) of ASA score. ^jASA II/III. ^kMean (range) of CCI. thMean (± SD) of CCI. ^mMedian (IQR) of CCI. ⁿCCI 0/1/2.

Eight NRCTs (34, 44, 46, 48, 50, 64, 67, 68) were not adequately matched in reviewed baseline characteristics such as age, gender, BMI, American Society of Anesthesiologists (ASA) score, comorbidities, malignancy rate, and tumor size. The tumors were larger in the OPD group than in the LPD group in the studies of Delitto et al. (48) and Stauffer et al. (64) There were more male patients in the OPD group than the LPD group in the studies of Croome et al. (46) and Tee et al. (67) Patients who have undergone LPD were slightly older than those who have undergone OPD in the study of Tran et al. (68) BMI was lower in the LPD group than the OPD group in the study of Dokmak et al. (50) Patients with ASA score of less than 3 were more in the LPD group than the OPD group in the study of Chopinet et al. (44) Malignant histologic subtypes and HTN were noted more in the OPD group in the study of Xourafas et al. (34) Although only malignances were included, pancreatic adenocarcinoma in the OPD group and ampullary adenocarcinoma in the LPD group were noted more in the study of Tan et al. (66)

Primary outcomes

There was no significant difference in postoperative mortality (OR 0.91, 95% CI 0.75–1.11, p = 0.35) (Figure 1). LPD was associated with a significant reduction in overall postoperative complications

(OR 0.80, 95% CI 0.73–0.87, p < 0.00001) (Figure 2). However, serious postoperative complications were comparable (OR 0.97, 95% CI 0.82–1.15, p = 0.74) (Figure 3). There was significantly shorter hospital stay in the LPD group with significant heterogeneity (MD –2.32 days, 95% CI –3.18 to –1.45, p < 0.00001; $I^2 = 87\%$, p < 0.00001); high heterogeneity was primarily observed in the NRCTs ($I^2 = 89\%$, p < 0.00001) (Figure 4).

Secondary outcomes

There was significantly longer operative time in the LPD group with significant heterogeneity (MD 85.59 min, 95% CI 58.25–112.94, p < 0.00001; $I^2 = 99\%$, p < 0.00001) (Figure 5). Estimated blood loss for LPD was less than that of OPD with significant heterogeneity (MD –173.84 ml, 95% CI –212.17 to –135.51, p < 0.00001; $I^2 = 95\%$, p < 0.00001) (Figure 6). Significant heterogeneities were observed for operative time and estimated blood loss in both RCTs and NRCTs ($I^2 = 87\%$, p < 0.0001; $I^2 = 99\%$, p < 0.00001; $I^2 = 90\%$, p < 0.0001; $I^2 = 96\%$, p < 0.0001; $I^2 = 96\%$, p < 0.0001; $I^2 = 96\%$, p < 0.0001). In addition, LPD showed a significantly lower intraoperative blood transfusion rate than LPD with significant heterogeneity (OR 0.62, 95% CI 0.48–0.80, p = 0.0002; $I^2 = 55\%$, p = 0.0003); heterogeneity was only observed in NRCTs ($I^2 = 60\%$, p = 0.0003) (Figure 7).

	LPD	,	OPD			Odds Ratio	Odd	s Ratio
Study or Subgrou					Weight	M-H, Fixed, 95% Cl		ed, 95% Cl
1.1.1 RCT	<u>, </u>					in right block of the		
Palanivelu 2017	1	32	1	32	0.5%	1.00 [0.06, 16.71]		
Poves 2018	ó	32	2	29	1.2%	0.17 [0.01, 3.68]	·	
van Hilst 2019	7	50	1	49		7.81 [0.92, 66.10]		
Wang M 2021	5	297	6	297	2.8%	0.83 [0.25, 2.75]		
Subtotal (95% CI)		411	0	407	4.8%	1.27 [0.56, 2.87]	-	
Total events	13	411	10	407	4.070	1.27 [0.30, 2.07]		
Heterogeneity: Ch		2 /D -		2006				
Test for overall eff				5570				
1.1.2 NRCT								
Asbun 2012	3	53	19	215	3.3%	0.62 [0.18, 2.17]		
Chen K 2021	1	101	1	101	0.5%	1.00 [0.06, 16.21]		
Chopinet 2018	3	65	17	290	2.8%	0.78 [0.22, 2.73]		
Croome 2014	1	108	4	214	1.2%	0.49 [0.05, 4.44]		
Dang C 2021	2	131	7	131	3.2%	0.27 [0.06, 1.35]		<u>+</u>
Delitto 2016	1	52	ó	50	0.2%	2.94 [0.12, 73.93]		
Ding W 2021	, 0	112	4	112		0.11 [0.01, 2.01]	· · ·	
Dokmak 2015	1	46	4	46	0.2%	3.07 [0.12, 77.24]		
El Nakeeb 2020	1	40	3	40	0.2%	0.66 [0.07, 6.55]		
Han SH 2020	1	104	0	113	0.9%	3.29 [0.13, 81.66]		
							_	_
Kantor 2017	41	828 95	391	7385		0.93 [0.67, 1.30]		
Katsuki 2021	1		1	380	0.2%	4.03 [0.25, 65.06]		
Khaled 2018	0	15	1	15	0.7%	0.31 [0.01, 8.28]	· · · · ·	
Kuesters 2018	5	62	13	278	2.0%	1.79 [0.61, 5.21]		
Mazzola 2021	2	50	3	50	1.4%	0.65 [0.10, 4.09]		
Meng LW 2018	1	58	1	58	0.5%	1.00 [0.06, 16.38]		
Tan CL 2015	0	30	1	30	0.7%	0.32 [0.01, 8.24]		
Tan JKH 2019	1	20	0	20	0.2%	3.15 [0.12, 82.16]		
Tee MC 2015	5	113	3	225	0.9%	3.43 [0.80, 14.60]	_	
Tran 2016	26	681		14893	29.7%	0.75 [0.50, 1.12]	-	-
Xourafas 2018	11	418	213	9963	7.9%	1.24 [0.67, 2.29]	-	
Zhang Z 2022	1	47	0	47	0.2%	3.06 [0.12, 77.16]		
Zhou W 2019	0	55	2	93	0.9%	0.33 [0.02, 6.99]		•
Subtotal (95% CI)		3281		34783	95.2%	0.89 [0.73, 1.09]	•	•
Total events	108		1434					
Heterogeneity: Ch	i ² = 16.96, df	= 22 (P	e = 0.77); i	²= 0%				
Test for overall eff	ect: Z = 1.10 ((P = 0.2	27)					
Total (95% CI)		3692		35190	100.0%	0.91 [0.75, 1.11]		•
Total events	121		1444					
Heterogeneity: Ch		= 26 (P		² = 0%			teres and the second se	+ +
Test for overall eff							0.01 0.1	1 10 100
Test for subaroup				1 (P = 0	.41), ² = 0	1%	Favours LPD) Favours OPD

FIGURE 1

Forest plot of comparison between LPD and OPD on postoperative mortality. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy.

	LPD		OP			Odds Ratio	Odds Rati	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95	5% CI
2.1.1 RCT								
Palanivelu 2017	8	32	10			0.73 [0.25, 2.19]		
Poves 2018	22	32	21	29	0.7%	0.84 [0.28, 2.53]		-
Wang M 2021	149	297	136	297	6.7%	1.19 [0.86, 1.64]		
Subtotal (95% CI)		361		358	8.2%	1.12 [0.83, 1.51]	+	
Total events	179		167					
Heterogeneity: Chi ²	= 0.98, df=	2 (P =	0.61); I ² :	= 0%				
Test for overall effe	ct: Z = 0.75	(P = 0.4	5)					
2.1.2 NRCT								
Ammori 2020	4	11	13	22	0.5%	0.40 [0.09, 1.76]		
Asbun 2012	25	53	138			0.50 [0.27, 0.91]		
Chen K 2021	23	101	32		2.5%	0.60 [0.32, 1.13]		
Chen XM 2018	10	47	15			0.72 [0.29, 1.80]		
Chopinet 2018	53	65	199					
						2.02 [1.03, 3.96]		
Conrad 2017	38	40	23			1.65 [0.22, 12.54]		
Dang C 2021	33	131	40		3.0%	0.77 [0.45, 1.32]		
Dokmak 2015	34	46	27	46		1.99 [0.83, 4.82]		
El Nakeeb 2020	27	37	64	74		0.42 [0.16, 1.13]		
Han SH 2020	37	104	45			0.83 [0.48, 1.45]		
Katsuki 2021	25	95	121	380		0.76 [0.46, 1.27]		
Khaled 2018	6	15	10			0.33 [0.08, 1.48]		
Kuesters 2018	25	62	107	278		1.08 [0.62, 1.89]		
Mazzola 2021	28	50	31	50	1.4%	0.78 [0.35, 1.73]		
Mendoza 2015	8	18	13	34	0.5%	1.29 [0.41, 4.12]		
Shin 2019	20	56	32	56	2.0%	0.42 [0.19, 0.89]		
Song KB 2015	25	93	26	93	1.9%	0.95 [0.50, 1.80]		
Stauffer 2016	31	58	129	193	2.8%	0.57 [0.31, 1.03]		
Tan JKH 2019	9	20	6		0.3%	1.91 [0.52, 7.01]		
Tran 2016	268	681		14893		0.76 [0.65, 0.89]	=	
Xourafas 2018	161	418	4480			0.77 [0.63, 0.94]		
Zhou W 2019	27	55	66			0.39 [0.20, 0.79]		
Subtotal (95% CI)	21	2256	00	27140		0.77 [0.70, 0.85]	•	
Total events	916	2200	12468	21110	0 110 /0	0111 [0110, 0100]		
Heterogeneity: Chi ²		- 21 /P		IZ - 01.00				
Test for overall effer				1 - 51%	,			
				0710-	100.00			
Total (95% CI)		2617		27498	100.0%	0.80 [0.73, 0.87]	•	
Total events	1095		12635					
Heterogeneity: Chi ^z				I ² = 35%	,		0.01 0.1 1	10
Test for overall effe							Favours LPD Fav	
Test for subaroup d	lifferences:	Chi ² = 5	5.60. df =	1 (P = 0)	1.02). I ² = 8	12.1%		ours o

FIGURE 2

Forest plot of comparison between LPD and OPD on overall postoperative complications. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy.


Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	_
3.1.1 RCT								-
Palanivelu 2017	3	32	4	32	1.3%	0.72 [0.15, 3.53]		
Poves 2018	5	32	11	29	3.5%	0.30 [0.09, 1.02]		
van Hilst 2019	25	50	19	49	3.4%	1.58 [0.71, 3.51]	_ 	
Wang M 2021	85	297	69	297	17.6%	1.32 [0.92, 1.92]	+ - -	
Subtotal (95% CI)		411		407	25.8%	1.19 [0.87, 1.63]	◆	
Total events	118		103					
Heterogeneity: Chi ² =	= 6.06, df =	3 (P =	0.11); I ² =	= 51%				
Test for overall effect	: Z = 1.09	(P = 0.2	27)					
3.1.2 NRCT								
Ammori 2020	1	11	5	22	1.1%	0.34 [0.03, 3.34]		
Asbun 2012	13	53	53	215	5.6%	0.99 [0.49, 2.00]		
Chen K 2021	11	101	15	101	4.8%	0.70 [0.30, 1.61]		
Chen XM 2018	2	47	3	55	0.9%	0.77 [0.12, 4.82]		
Chopinet 2018	26	65	64	290	5.0%	2.35 [1.33, 4.16]		
Conrad 2017	24	40	17	25	3.0%	0.71 [0.25, 2.02]		
Croome 2014	6	108	29	214	6.6%	0.38 [0.15, 0.93]		
Delitto 2016	13	52	16	50	4.4%	0.71 [0.30, 1.68]		
Dokmak 2015	13	46	9	46	2.3%	1.62 [0.61, 4.28]		
El Nakeeb 2020	5	37	10	74	2.1%	1.00 [0.32, 3.17]		
Khaled 2018	4	15	7	15	1.8%	0.42 [0.09, 1.92]		
Mazzola 2021	15	50	14	50	3.5%	1.10 [0.46, 2.62]		
Mendoza 2015	3	18	7	34	1.4%	0.77 [0.17, 3.43]		
Meng LW 2018	9	58	9	58	2.7%	1.00 [0.37, 2.73]		
Mesleh 2013	23	75	15	48	4.5%	0.97 [0.44, 2.13]		
Shin 2019	3	56	6	56	2.0%	0.47 [0.11, 1.99]		
Song KB 2015	7	93	5	93	1.7%	1.43 [0.44, 4.69]		
Stauffer 2016	13	58	58	193	7.4%	0.67 [0.34, 1.34]		
Tan JKH 2019	3	20	4	20	1.2%	0.71 [0.14, 3.66]		
Tee MC 2015	11	113	34	225	7.3%	0.61 [0.29, 1.25]		
Zhang Z 2022	8	47	6	47	1.8%	1.40 [0.45, 4.41]		
Zhou W 2019	6	55	13	93	3.1%	0.75 [0.27, 2.11]		
Subtotal (95% CI)		1218		2024	74.2%	0.90 [0.74, 1.09]	•	
Total events	219		399					
Heterogeneity: Chi ² =				² = 8%				
Test for overall effect	: Z = 1.08	(P = 0.2	28)					
Total (95% CI)		1629		2431	100.0%	0.97 [0.82, 1.15]	•	
Total events	337		502					
Heterogeneity: Chi ² =	: 30.96, df	= 25 (P	P = 0.19);	I ² = 199	%		0.01 0.1 1 10 100	

FIGURE 3

Forest plot of comparison between LPD and OPD on serious postoperative complications. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy.


Study or Subgroup	LPD Mean SD	Total Mean	OPD	Total W	loinht	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl	
4.1.1 RCT	mean SD	istai medi	30	Total W	rətyrit	rv, nanuom, 93% Cl	IV, Randolli, 35% Cl	
Palanivelu 2017	7 11.75	32 13	6	32	2.0%	-6.00 [-10.57, -1.43]	·	
Poves 2018	13.5 12.25	32 17	36	29	0.4%	-3.50 [-17.27, 10.27]		
van Hilst 2019	12.8 9.9	50 12.5	9.9	49	2.4%	0.30 [-3.60, 4.20]		
Wang M 2021	17.2 8.3	297 19	10.3	297	4.1%	-1.80 [-3.30, -0.30]		
Subtotal (95% CI)		411		407	8.9%	-2.13 [-4.39, 0.13]		
Heterogeneity: Tau ²			0.22); I² =	32%				
Test for overall effec	t: Z = 1.85 (P = 0.	06)						
4.1.2 NRCT								
Ammori 2020	5 1.3	11 8.6	2	22	4.3%	-3.80 [-4.94, -2.66]		
Asbun 2012	8 3.2				4.1%	-4.40 [-5.83, -2.97]		
Chen K 2021	14 10	101 18	6.8	101	3.5%	-4.00 [-6.36, -1.64]		
Chen XM 2018	13 4	47 18	5.5	55	3.8%	-5.00 [-6.85, -3.15]	(
Choi 2020	21.19 11.13	27 19.94	9.79	34	1.7%	1.25 [-4.08, 6.58]		_
Chopinet 2018	25 6.3	65 17	2	290	4.1%	8.00 [6.45, 9.55]		—
Conrad 2017	24.5 75.5	40 61	42	25	0.1%	-36.50 [-65.11, -7.89]		
Croome 2014	6 19	108 9	11.3	214	2.4%	-3.00 [-6.89, 0.89]		
Dang C 2021	18 1.7	131 21	1.7	131	4.6%	-3.00 [-3.41, -2.59]	+	
Delitto 2016	9 5	52 11.9	7.8	50	3.3%	-2.90 [-5.45, -0.35]		
Ding W 2021	21.2 15.8	112 25.5	27.5	112	1.5%	-4.30 [-10.17, 1.57]	•	
Dokmak 2015	25 24.5				0.6%	2.00 [-8.54, 12.54]		
El Nakeeb 2020	7 15	37 10			1.8%	-3.00 [-7.97, 1.97]		
Han SH 2020	18.3 13.9				3.0%	0.40 [-2.63, 3.43]		
Kantor 2017	10.2 8.5				4.6%	-1.60 [-2.22, -0.98]	-	
Katsuki 2021	23.2 12.8				3.1%	-3.00 [-5.87, -0.13]		
Khaled 2018	11.3 4					-10.70 [-17.29, -4.11]	•	
Kuesters 2018	14 8				1.0%	-2.00 [-9.59, 5.59]		-
Lee CS 2018	14.74 5.4	31 23.81			2.1%	-9.07 [-13.58, -4.56]	•	
Mazzola 2021	15.4 9.2				2.6%	-5.30 [-8.91, -1.69]		
Mendoza 2015	12.6 8.8	18 21.2			1.0%	-8.60 [-16.26, -0.94]		
Meng LVV 2018	14.1 4.8	58 14.8			3.6%	-0.70 [-2.84, 1.44]		
Mesleh 2013	7 10.7	75 8			2.6%	-1.00 [-4.62, 2.62]		
Shin 2019 Song KB 2015	13.5 11.3 14.3 7.8	56 15.7 93 19.2			2.1% 3.4%	-2.20 [-6.65, 2.25]		
	14.3 7.8	93 19.2 58 9			2.1%	-4.90 [-7.29, -2.51]		
Stauffer 2016 Tan CL 2015	9.97 3.74	30 11.87			2.1%	-3.00 [-7.41, 1.41] -1.90 [-4.05, 0.25]		
Tan JKH 2019	17.8 9.3	20 20			3.0%	-2.20 [-8.68, 4.28]		
Tran 2016	11.7 5.9				4.6%	-2.10 [-2.56, -1.64]	+	
Xourafas 2018	11 9.4	418 11			4.4%	0.00 [-0.92, 0.92]	+	
Yoo 2020	13.7 10.8				2.7%	-3.60 [-6.98, -0.22]		
Zhang Z 2022	17 7.6	47 17			2.7%	0.00 [-3.41, 3.41]		
Zhou W 2019	14.8 6.9				3.5%	0.10 [-2.28, 2.48]		
Subtotal (95% CI)	0.0	3693			91.1%	-2.33 [-3.25, -1.41]	◆	
Heterogeneity: Tau ²	= 4.36: Chi ² = 28	0.81. df = 32 (P < 0.000					
Test for overall effect								
Total (95% CI)		4104		35625 10	00.0%	-2.32 [-3.18, -1.45]	•	
Heterogeneity: Tau ²	- 4 10: Chiž - 20					-2.32 [-3.18, -1.45]		
Test for overall effect			~ ~ 0.000	JUT), E = 87	01.10		-10 -5 0 5	10
Test for subgroup d			= 0.87)	I ² = 0%			Favours LPD Favours OPE	C
restion subdroup u	merchices. offr =	5.55. ui – T tr	- 0.073.	0 %				

and OPD on hospital stay. LPD, laparoscopic pancr D, op



There were no significant differences between LPD and OPD in terms of POPF (OR 0.93, 95% CI 0.81–1.06, p = 0.29), PPH (OR 1.10, 95% CI 0.87–1.39, p = 0.42), and BL (OR 1.28, 95% CI 0.86–1.89, p = 0.22) (Figures 8, 9, 10). However, a lower DGE rate was observed in the LPD group (OR 0.78, 95% CI 0.67–0.91, p = 0.002) (Figure 11). The number of harvested lymph nodes was similar in both groups with significant heterogeneity (MD 0.66, 95% CI –0.11–1.44, p = 0.09; $l^2 =$

87%, p < 0.00001), and heterogeneity was significant in both RCTs and NRCTs ($I^2 = 91\%$, p < 0.00001; $I^2 = 86\%$, p < 0.00001; respectively) (Figure 12). However, a higher R0 resection rate was found in the LPD group (OR 1.25, 95% CI 1.09–1.43, p = 0.001) (Figure 13). No significant differences in reoperation (OR 1.10, 95% CI 0.88–1.37, p = 0.41) and unplanned readmission (OR 0.95, 95% CI 0.81–1.10, p = 0.46) were found between LPD and OPD (Supplementary Figures 3, 4).



Forest plot of comparison between LPD and OPD on estimated blood loss. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy.

	LPD		OPI			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
7.1.1 RCT							
Palanivelu 2017	3	32	7	32	2.4%	0.37 [0.09, 1.58]	
Poves 2018	10	32	10	29	3.7%	0.86 [0.30, 2.52]	
Wang M 2021	67	297	91	297	8.9%	0.66 [0.46, 0.95]	
Subtotal (95% CI)		361		358	15.0%	0.66 [0.47, 0.92]	•
Total events	80		108				
Heterogeneity: Tau² = Test for overall effect				P = 0.65	; I² = 0%		
7.1.2 NRCT							
Chen K 2021	14	101	22	101	5.7%	0.58 [0.28, 1.21]	
Choi 2020	0	27	2	34	0.6%	0.24 [0.01, 5.14]	
Chopinet 2018	3	65	66	290	3.2%	0.16 [0.05, 0.54]	
Conrad 2017	14	40	10	25	3.9%	0.81 [0.29, 2.26]	.
Croome 2014	21	108	71	214	7.2%	0.49 [0.28, 0.85]	
Delitto 2016	4	52	4	50	2.4%	0.96 [0.23, 4.06]	
Ding W 2021	7	112	23	112	4.6%	0.26 [0.11, 0.63]	
Dokmak 2015	5	46	4	46	2.6%	1.28 [0.32, 5.11]	
El Nakeeb 2020	11	37	26	74	4.9%	0.78 [0.33, 1.83]	
Kuesters 2018	9	62	65	278	5.5%	0.56 [0.26, 1.19]	
Lee CS 2018	9	31	18	31	3.8%	0.30 [0.10, 0.85]	
Mendoza 2015	1	18	1	34	0.7%	1.94 [0.11, 32.99]	
Meng LW 2018	11	58	9	58	4.2%	1.27 [0.48, 3.35]	
Stauffer 2016	15	58	90	193	6.3%	0.40 [0.21, 0.77]	
Tan CL 2015	0	30	30	30	0.5%	0.32 [0.01, 8.24]	
Tan JKH 2019	5	20	5	20	2.4%	1.00 [0.24, 4.18]	
Tee MC 2015			110				
	26	113		225	7.6%	0.31 [0.19, 0.52]	
Tran 2016	137	681		14893	10.3%	0.75 [0.62, 0.91]	
Yoo 2020	9	69	10	69	4.2%	0.89 [0.34, 2.33]	
Zhou W 2019	16	55	7	93	4.2%	5.04 [1.92, 13.24]	▲ <u> </u>
Subtotal (95% CI)		1783		16870	85.0%	0.62 [0.46, 0.84]	•
Total events	317		4271				
Heterogeneity: Tau² = Test for overall effect				9 (P = 0.	0003); I² =	: 60%	
Total (95% CI)		2144		17228	100.0%	0.62 [0.48, 0.80]	◆
Total events	397		4379				
Heterogeneity: Tau ² =		² = 48.6		2 (P = 0.	0009): I ^z =	55%	
Test for overall effect					/		0.01 0.1 i 10 10
Test for subaroup dif				1 /P = 0	01) 12 - 0	96	Favours LPD Favours OPD

FIGURE 7

Forest plot of comparison between LPD and OPD on intraoperative blood transfusion. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy.

	LPD		OPD			Odds Ratio	Odds	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixe	d, 95% Cl
8.1.1 RCT		~~~			0.00	0 43 10 00 0 351		
Palanivelu 2017	2	32 32	4	32 29	0.9%	0.47 [0.08, 2.75]		
Poves 2018			8		1.7%	0.38 [0.10, 1.41]		
van Hilst 2019	14	50	12	49	2.0%	1.20 [0.49, 2.94]		<u> </u>
Wang M 2021	29	297	33	297	6.8%	0.87 [0.51, 1.47]		
Subtotal (95% CI)		411		407	11.4%	0.82 [0.54, 1.24]		
Total events	49	2.00-1	57	0.04				
Heterogeneity: Chi ² =				0%				
Test for overall effect	CZ=0.93 ((P = 0.3)	5)					
8.1.2 NRCT								
Ammori 2020	1	11	3	22	0.4%	0.63 [0.06, 6.91]		
Asbun 2012	4	53	15	215	1.3%	1.09 [0.35, 3.42]		
Chen K 2021	12	101	16	101	3.2%	0.72 [0.32, 1.60]		_
Chen XM 2018	6	47	8	55	1.5%	0.86 [0.28, 2.68]		
Choi 2020	2	27	4	34	0.8%	0.60 [0.10, 3.55]		
Chopinet 2018	16	65	36	290	2.3%	2.30 [1.19, 4.47]		
Conrad 2017	12	40	10	25	2.0%	0.64 [0.23, 1.83]		
Croome 2014	12		26	214	3.6%	0.90 [0.44, 1.87]		
Dang C 2021	19	131	29	131	5.7%	0.60 [0.32, 1.13]		-
Delitto 2016	6	52	13	50	2.7%	0.37 [0.13, 1.07]		
Ding W 2021	18	112	7	112	1.4%	2.87 [1.15, 7.18]		
Dokmak 2015	20	46	15	46	1.9%	1.59 [0.68, 3.71]	_	
El Nakeeb 2020	5	37	10	74	1.3%	1.00 [0.32, 3.17]		
Han SH 2020	13	104	21	113	4.0%	0.63 [0.30, 1.32]		_
Katsuki 2021	16	95	85	380	6.5%	0.70 [0.39, 1.27]		_
Khaled 2018	3	15	4	15	0.7%	0.69 [0.12, 3.79]		
Lee CS 2018	4	31	1	31	0.2%	4.44 [0.47, 42.26]		
Mazzola 2021	7	50	9	50	1.8%	0.74 [0.25, 2.18]		
Mendoza 2015	2	18	3	34	0.4%	1.29 [0.20, 8.53]		
Meng LW 2018	8	58	8	58	1.6%	1.00 [0.35, 2.87]		
Mesleh 2013	7	75	3	48	0.8%	1.54 [0.38, 6.29]		
Shin 2019	4	56	12	56	2.6%	0.28 [0.08, 0.94]		
Song KB 2015	6	93	6	93	1.3%	1.00 [0.31, 3.22]		
Stauffer 2016	4	58	14	193	1.4%	0.95 [0.30, 3.00]		
Tan CL 2015	1	30	3	30	0.7%	0.31 [0.03, 3.17]		
Tan JKH 2019	2	20	1	20	0.2%	2.11 [0.18, 25,35]		
Tee MC 2015	26	113	57	225	6.7%	0.88 [0.52, 1.50]		_
Xourafas 2018	81	418	1789	9963	26.7%	1.10 [0.86, 1.41]	-	-
Yoo 2020	6	69	15	69	3.1%	0.34 [0.12, 0.95]		
Zhang Z 2022	4	47	5	47	1.1%	0.78 [0.20, 3.11]		
Zhou W 2019	4	55	5	93	0.8%	1.38 [0.35, 5.37]		·
Subtotal (95% CI)	-	2235		12887	88.6%	0.94 [0.82, 1.09]	•	
Total events	331	2200	2233	12001	001070	0104 [0102, 1100]		
Heterogeneity: Chi ² =		= 30 (P		² = 17%				
Test for overall effect				- 11 %				
Total (95% CI)		2646		13294	100.0%	0.93 [0.81, 1.06]	٠	
Total events	380		2290					
Heterogeneity: Chi² =	= 39.04, df	= 34 (P	= 0.25); l	² = 13%				40
Test for overall effect							0.01 0.1 1	10
Test for subaroup dif				1 /P – 0	54) B - 0	196	Favours LPD	Favours OPD

FIGURE 8

Forest plot of comparison between LPD and OPD on postoperative pancreatic fistula. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy.

Study or Subgroup	LPI		OPD		Moight	Odds Ratio M-H, Fixed, 95% CI	Odds Ratio M-H. Fixed. 95% Cl
9.1.1 RCT	Events	TULAI	Events	TULAI	weight	M-H, FIXeu, 95% CI	M-H, FIAEU, 95% CI
Palanivelu 2017	2	32	2	32	1.4%	1.00 [0.13, 7.57]	
Poves 2018	3	32	6	29	4.3%	0.40 [0.09, 1.76]	
van Hilst 2019	5	50	7	49	4.8%	0.67 [0.20, 2.26]	
Wang M 2021	24	297	25		4.0%	0.96 [0.53, 1.72]	
Subtotal (95% CI)	24	411	20	407	27.7%	0.82 [0.51, 1.33]	
Total events	34		40	101	2.111 /0	oloc [olo i, iloo]	
Heterogeneity: Chi ² =		3 (P =		. 0%			
Test for overall effect				. 0 .0			
9.1.2 NRCT							
Asbun 2012	3	53	11	215	3.1%	1.11 [0.30, 4.14]	
Chen K 2021	4	101	3	101	2.2%	1.35 [0.29, 6.18]	
Chen XM 2018	1	47	2	55	1.4%	0.58 [0.05, 6.56]	
Choi 2020	Ó	27	1	34	1.0%	0.41 [0.02, 10.37]	
Chopinet 2018	14	65		290	10.3%	1.38 [0.71, 2.70]	
Croome 2014	8	108		214	6.0%	1.24 [0.50, 3.08]	
Dang C 2021	10	131		131	7.6%	0.90 [0.37, 2.20]	
Delitto 2016	5	52	3	50	2.1%	1.67 [0.38, 7.38]	
Dokmak 2015	11	46	3	46	1.7%	4.50 [1.17, 17.42]	
Han SH 2020	2	104	2	113	1.4%	1.09 [0.15, 7.87]	
Katsuki 2021	11	95	50	380	13.2%	0.86 [0.43, 1.73]	
Mazzola 2021	6	50	3	50	2.0%	2.14 [0.50, 9.07]	
Meng LVV 2018	4	58	3	58	2.1%	1.36 [0.29, 6.36]	
Stauffer 2016	3	58	7	193	2.3%	1.45 [0.36, 5.79]	
Tan CL 2015	1	30	1	30	0.7%	1.00 [0.06, 16.76]	
Tan JKH 2019	1	20	2	20	1.4%	0.47 [0.04, 5.69]	
Tee MC 2015	9	113	19	225	8.8%	0.94 [0.41, 2.15]	
Zhang Z 2022	5	47	3	47	2.0%	1.75 [0.39, 7.77]	
Zhou W 2019	4	55	6	93	3.1%	1.14 [0.31, 4.22]	
Subtotal (95% CI)		1260		2345	72.3%	1.21 [0.92, 1.57]	♠
Total events	102		191				
Heterogeneity: Chi ² =				= 0%			
Test for overall effect	: Z = 1.38	(P = 0.1	7)				
Total (95% CI)		1671		2752	100.0%	1.10 [0.87, 1.39]	•
Total events	136		231				
Heterogeneity: Chi ² =	= 11.02, df	= 22 (P	= 0.97);	I² = 0%			
Test for overall effect	: Z = 0.80	(P = 0.4)	2)				Favours LPD Favours OPD
Test for subaroup dif	ferences:	Chi ^z = '	.88. df=	1 (P =	0.17). I ^z =	46.8%	
							e. LPD, laparoscopic pancreaticoduodenector

Subgroup analysis and publication bias

Although the results of overall postoperative complications, hospital stay, DGE, and R0 resection were significantly different between LPD and OPD in the overall analysis, the subgroup analysis results showed consistent effects only in NRCTs and no significant differences in RCTs. However, the results of operative time, estimated blood loss, and intraoperative blood transfusion were significantly different in both RCTs and NRCTs. The subgroup analysis results are partially summarized in Supplementary Table 2. The results of the postoperative mortality remained unchanged and had low heterogeneity among all subgroups evaluated. The reduction in overall postoperative complications was not significant when studies analyzed no more than 50 LPD cases (OR 0.85, 95% CI 0.61–1.18, p = 0.33) or baseline matching incomplete (OR 0.90, 95% CI 0.67–1.20, p = 0.46). The comparable result of serious postoperative complications favored LPD when studies analyzed all malignancies (OR 0.68, 95% CI 0.51–0.90, p = 0.008).

	LPE		OPE			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl	
10.1.1 RCT									
Palanivelu 2017	3	32	2	32		1.55 [0.24, 9.97]			
Poves 2018	1	32	3	29	6.9%	0.28 [0.03, 2.85]			
van Hilst 2019	6	50	5	49	10.1%	1.20 [0.34, 4.22]			
Wang M 2021	15	297	11	297	23.8%	1.38 [0.62, 3.06]			
Subtotal (95% CI)		411		407	45.0%	1.19 [0.65, 2.16]		+	
Total events	25		21						
Heterogeneity: Chi ²	= 1.71, df =	3 (P =	0.63); l ^a =	:0%					
Test for overall effec	t: Z = 0.56	(P = 0.5	7)						
10.1.2 NRCT									
Chen K 2021	2	101	3	101	6.7%	0.66 [0.11, 4.04]			
Chen XM 2018	1	47	1	55	2.1%	1.17 [0.07, 19.30]			-
Chopinet 2018	4	65	15	290	11.7%	1.20 [0.39, 3.75]			
Dang C 2021	1	131	0	131	1.1%	3.02 [0.12, 74.89]			
Dokmak 2015	2	46	2	46	4.4%	1.00 [0.13, 7.42]			
El Nakeeb 2020	4	37	6	74	8.1%	1.37 [0.36, 5.20]			
Katsuki 2021	1	95	5	380	4.5%	0.80 [0.09, 6.91]			
Mazzola 2021	3	50	3	50	6.4%	1.00 [0.19, 5.21]			
Meng LW 2018	2	58	2	58	4.4%	1.00 [0.14, 7.35]			
Tan CL 2015	1	30	0	30	1.1%	3.10 [0.12, 79.23]			
Zhou W 2019	6	55	3	93	4.5%	3.67 [0.88, 15.33]		+	
Subtotal (95% CI)		715		1308	55.0%	1.35 [0.81, 2.26]		*	
Total events	27		40						
Heterogeneity: Chi ²	= 3.56, df =	10 (P =	= 0.97); l ^a	= 0%					
Test for overall effect	t: Z = 1.14	(P = 0.2	6)						
Total (95% CI)		1126		1715	100.0%	1.28 [0.86, 1.89]		•	
Total events	52		61						
Heterogeneity: Chi ²	= 5.32. df =	14 (P =	= 0.98); *	= 0%			<u> </u>	<u> </u>	
Test for overall effect							0.01	0.1 1 10	100
Test for subgroup d				1 (P =	0.75). P=	0%		Favours LPD Favours OPD	

Forest plot of comparison between LPD and OPD on bile leak. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy.

~	LPI		OPE			Odds Ratio		s Ratio
Study or Subgr 11.1.1 RCT	oup Events	lotal	Events	lotal	weight	M-H, Fixed, 95% Cl	M-H, HX	ed, 95% Cl
			-		4.50	0.00 10 40 0.001		
Palanivelu 2017		32	7	32	1.5%	0.66 [0.19, 2.36]		
Poves 2018	3	32		29	1.7%	0.33 [0.08, 1.40]		
van Hilst 2019	17 38	50 297	10	49	1.7%	2.01 [0.81, 4.98]	_	
Wang M 2021 Subtatal (05% C		411	41	297 407	9.2% 14.2%	0.92 [0.57, 1.47] 0.95 [0.65, 1.39]		
Subtotal (95% C	-1) 63	411	65	407	14.270	0.95 [0.05, 1.59]		T
Total events		2 (7)		1000				
Heterogeneity: Test for overall				40%				
rest for overall	enect: $Z = 0.27$	(P = 0.7	9)					
11.1.2 NRCT								
Asbun 2012	5	53	21	215	1.9%	0.96 [0.35, 2.68]		<u> </u>
Chen K 2021	2	101	5	101	1.3%	0.39 [0.07, 2.05]		
Chen XM 2018	2	47	2	55	0.5%			
Choi 2020	1	27	2	34	0.5%	1.18 [0.16, 8.70] 0.62 [0.05, 7.17]		
Chopinet 2018	6	65	26	290	2.2%			
Croome 2014	10	108	39	230	6.1%	1.03 [0.41, 2.62] 0.46 [0.22, 0.96]		_
Dang C 2021	20	131	36	131	7.9%	0.48 [0.22, 0.88]		_
Dokmak 2015	20	46	50	46	1.5%	1.17 [0.39, 3.55]		
El Nakeeb 2020		40	12	40	1.3%	0.81 [0.26, 2.49]		
Han SH 2020	, J 16	104	19	113	4.0%	0.90 [0.44, 1.86]		•
Lee CS 2018	3	31	4	31	0.9%	0.72 [0.15, 3.54]		
Mazzola 2021	3	50	6	50	1.5%	0.47 [0.11, 1.99]		<u>+</u>
Mendoza 2015	0	18	2	34	0.4%	0.35 [0.02, 7.72]		
Meng LW 2018	9	58	9	58	2.0%	1.00 [0.37, 2.73]		<u> </u>
Mesleh 2013	10	75	4	48	1.1%	1.69 [0.50, 5.74]		
Song KB 2015	1	93	2	93	0.5%	0.49 [0.04, 5.55]		
Stauffer 2016	6	58	16	193	1.7%	1.28 [0.48, 3.43]		
Tan CL 2015	2	30	3	30	0.7%	0.64 [0.10, 4.15]		
Tan JKH 2019	2	20	3	20	0.7%	0.63 [0.09, 4.24]		
Tee MC 2015	27	113	79	225	10.4%	0.58 [0.35, 0.97]		-
Xourafas 2018	71	418	1680	9963	29.0%	1.01 [0.78, 1.31]		+
Yoo 2020	4	69	10	69	2.4%	0.36 [0.11, 1.22]		+
Zhang Z 2022	4	47	12	47	2.8%	0.27 [0.08, 0.92]		-
Zhou W 2019	1	55	21	93	4.0%	0.06 [0.01, 0.49]	← → →	
Subtotal (95% C	D	1854		12227	85.8%	0.75 [0.64, 0.89]	•	•
Total events	218		2020					
Heterogeneity:		= 23 (P	= 0.31):	² = 11%				
Test for overall								
Total (95% CI)		2265		12634	100.0%	0.78 [0.67, 0.91]	•	
Total events	281		2085					
Heterogeneity:	Chi² = 31.59, df	= 27 (P	= 0.25);	² = 15%			0.01 0.1	1 10 100
Test for overall	effect: Z = 3.16	(P = 0.0)	02)					Favours OPD
Test for subaro	up differences:	Chi ^z = '	.19. df=	1 (P = 0	27). I² = 1	16.2%	i avouis LFD	

Although heterogeneity remained high, the overall effect of hospital stay remained unchanged in the subgroup analysis, except that studies involved baseline matching incomplete, which became comparable between the two procedures (MD -0.16 days, 95% CI -3.18 to 2.87, p = 0.92).


The results of operative time and estimated blood loss remained unchanged and had high heterogeneity among all subgroups evaluated. The lower intraoperative blood transfusion rate became not significant when studies analyzed all malignancies (OR 0.76, 95% CI 0.50–1.16, p = 0.20) and no more than 50 LPD cases (OR 0.67, 95% CI 0.45–1.00, p = 0.05). A similar number of lymph nodes remained unchanged and had high heterogeneity among all subgroup analyses, except for subgroups of more than 50 LPD cases (MD 2.00, 95% CI 0.83–3.16, p = 0.0008), which favored LPD. Funnel plot analysis of the postoperative mortality and hospital stay indicates that the publication bias of these studies was not obvious (Supplementary Figure 5).

Discussion

This meta-analysis compared the perioperative outcomes of LPD to OPD based on both RCTs and NRCTs, which included 4,262 patients who have undergone LPD. To our knowledge, it is the largest meta-analysis to date comparing LPD and OPD for pancreatic and periampullary tumors. From the perspective of pooled analysis results, this study supports the ongoing trend of laparoscopic surgery to cure tumors of the pancreatic head and periampullary

region. Our findings clearly demonstrate that LPD leads to lower overall postoperative complications, hospital stay, estimated blood loss, intraoperative blood transfusion, and DGE, and it improves R0 resection rate with similar retrieval of lymph nodes. Rates of postoperative mortality, serious postoperative complications, POPF, PPH, BL, reoperation, and unplanned readmission are comparable between LPD and OPD. However, the duration of surgery is longer for patients undergoing LPD.

Published meta-analyses that only included RCTs were incomplete, and data from a small volume of cases prevented a valid comparison between LPD and OPD. The recent meta-analyses included three RCTs that did not show any difference between LPD and OPD except for longer operative time and lower blood loss in LPD (14-16). However, these findings were limited due to the high risk of bias and low certainty of evidence. As the surgeons in three RCTs (35-37) might not have surmounted the learning curve for LPD, the non-significant results pooled from RCTs did not mean that the LPD had no advantage over OPD, and these results should be interpreted with caution. Moreover, no subgroup analysis was performed in any of these studies due to the small number of patients and events included. In our analysis, more cases from NRCTs were analyzed. Quality assessment of the included NRCTs was based on a validated tool developed for NRCT evaluation, as well as 24 of which had a high-quality score and constituted two-thirds of the included studies. In consistent with these RCT meta-analyses, our analysis also showed LPD reduced blood loss and prolonged operative time. Although there was high heterogeneity within included studies



and among subgroup analyses, it suggested a consistent difference. In addition, lower intraoperative blood transfusion was found in this meta-analysis, which had significant differences in both the RCT and NRCT subgroups.

Recently, several meta-analyses have been conducted comparing LPD to OPD for pancreatic ductal adenocarcinoma (17-19). The studies of Sun et al. (17) and Feng et al. (19) showed a higher R0 rate in LPD, whereas Chen et al. (18) found no significant difference between the techniques. The meta-analysis of Sun et al. (17) showed lower intraoperative blood transfusion in LPD, whereas Feng et al. (19) showed no difference. The meta-analysis of Sun et al. (17) just showed shorter hospital stay in LPD, while Feng et al. (19) further demonstrated less overall morbidity, serious postoperative complications, and estimated blood loss in LPD. However, the meta-analysis of Sun et al. (17) included a study about robotic PD (RPD), whereas Chen et al. (18) did not include two eligible studies of Kantor et al. (32) and Delitto et al. (48) Furthermore, both metaanalyses of Sun et al. (17) and Feng et al. (19) included two studies of Kantor et al. (32) and Chapman et al. (30), which reported overlapped patient data from the NCDB. One recent network meta-analysis from Kamarajah et al. (20) compared open, laparoscopic, and robotic PD for periampullary cancers and showed similar mortality, serious complications, POPF, BL, and R0 resection between LPD and OPD, but shorter hospital stay and higher retrieval of lymph nodes in LPD. Another similar network meta-analysis from Aiolfi et al. (21) compared open, laparoscopic, and robotic PD in the setting of the malignant, borderline, or benign disease and also showed similar mortality, serious complications, POPF, lymph nodes retrieved, and R0 resection between LPD and OPD, but reduced hospital stay, estimated blood loss, overall postoperative complications, and readmission in LPD. However, the two network analyses included studies of Kantor et al. (32), Chapman et al. (30), and Sharpe et al. (31), which reported overlapped data from NCDB, as well as studies of Xourafas et al. (34) and Zimmerman et al. (33), which presented overlapped data from NSQIP. Overall, these previous meta-analyses showed inconstant results and suffered some degree of bias. Compared to these previous studies, our analyses excluded the possible overlapped patient data and conducted a comparison specifically for LPD and OPD. Furthermore, our study performed subgroup analysis in terms of all malignancies, benign and malignant, LPD cases of 50 or less, LPD cases of more than 50, baseline matching incomplete, and baseline matching complete, which might add precision to our comparison of LPD versus OPD.

Our meta-analyses support the notion that LPD is equally safe as the conventional open approach. There was no significant difference regarding the rate of postoperative mortality, serious postoperative complications, POPF, PPH, BL, reoperation, and unplanned readmission. Over the last decade, increasing improvements in equipment and surgical technique have extended indications of LPD (1, 2). Despite these advances, perioperative mortality remains up to 3% for LPD in high-volume centers (3, 4). The postoperative mortality rates of LPD and OPD for pancreatic and periampullary tumors in our meta-analysis were comparable (3.3% and 4.1%, respectively). With no significant difference, serious postoperative complication rates for LPD and OPD in our meta-analysis were 20.7% and 20.6%, respectively. Pancreas-specific complications such as POPF, PPH, and BL are common morbidity after pancreatic surgery, which accounted for the main cause of surgical mortality (72-74). Severe POPF, PPH, or BL is a dreaded adverse event that may cause metabolic disorders, peritonitis, intraperitoneal empyema

or abscess, anemia, sepsis, shock, and sometimes reoperation, as well as leads to fasting accompanying intravenous nutrition and prolonged hospital stay (72–74). Almost all of the included studies defined these complications according to the International Study Group of Pancreatic Surgery (ISGPS) (72–74), most of which reported clinically relevant grades (grades B and C). Consistent with the results of most existing clinical studies (35–38), the analyses of these complications for LPD and OPD in our meta-analysis were comparable and had high homogeneity within included studies. Overall, LPD has been shown to be comparable to OPD in the safety related to the operation for the treatment of pancreatic and periampullary tumors.

One striking finding for our meta-analysis was decreased DGE in the LPD versus OPD. Although not imminently life-threatening, DGE remains the most common complication after PD, which causes significant discomfort and results in prolonged hospital stay (75). A review study assessed the average rate of clinically relevant DGE (grades B and C) after PD was 14.3% according to the ISGPS definition (76). Consistently, as most of the included studies reported clinically relevant DGE according to the ISGPS definition, DGE rates for LPD and OPD in our meta-analysis were 12.4% and 16.5%, respectively. The exact mechanisms of DGE are still unclear and are mostly multifactorial results involving vagal denervation. A recent retrospective study demonstrated that preservation of the hepatic branch of the vagus nerve could help reduce the incidence of DGE during LPD (77). These results are likely to be related to fine dissection and meticulous manipulation, as laparoscopic surgery offers a magnified view that facilitates precise identification of nerves and effective prevention of excessive nerve injury. A potential advantage of LPD is that reducing DGE incidence should be taken into account, and prospective studies are warranted to validate this effect in the future.

LPD is a more technically demanding and time-consuming procedure, which can be attributed to the challenging dissection of the pancreatic head and difficult reconstruction of the digestive tract by laparoscopic tools. Due to the complicated operation process, it is generally accepted that achieving a good level of surgical proficiency for LPD requires a long learning curve. Some studies have shown the number of cases required to surmount the learning curve ranged from 40 to 60 LPD cases (78). The included RCTs had reported their surgeons' LPD experience when the trials started, which is all less than 40 LPD cases except for the RCT of Wang et al. (38) with at least 104 LPD cases. As is the case with all surgical studies, the surgeon's technical proficiency plays an important role in the postoperative outcomes of LPD. Unfortunately, most included NRCTs did not explicitly describe their proficiency in LPD, which prevented subgroup analysis addressing relations between surgical proficiency and outcomes. Nevertheless, most of the included studies were carried out at large-volume hospitals, and therefore, LPD is likely not appropriate for low-volume hospitals (2, 4). We believe that LPD should only be implemented in high-volume centers by experienced specialists who have performed a sufficient amount of procedures and surmounted the learning curve for LPD.

With conducted analysis specifically for all malignancies, the comparable result of serious postoperative complications favored LPD. In addition, the pooled estimate showed a higher R0 rate for LPD. Given the higher surgical requirement for malignancy, surgeons' selection bias could have influenced these results, and

~	LPI		OPE			Odds Ratio	Odds Ratio	
Study or Subgroup 13.1.1 RCT	Events	lotal	Events	lotal	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	
Palanivelu 2017	24		20		0.00	0.07/0.40.04.041		_
	31	32	30	32	0.2%	2.07 [0.18, 24.01]		
Poves 2018	19		15	29	1.6%	1.36 [0.49, 3.76]		
van Hilst 2019	41	50	37	49	1.7%	1.48 [0.56, 3.90]		
Wang M 2021	290		288	297	1.7%	1.29 [0.48, 3.52]		
Subtotal (95% CI)		411		407	5.3%	1.41 [0.81, 2.46]	-	
Total events	381		370					
Heterogeneity: Chi ²				0%				
Test for overall effec	et: Z = 1.20	(P = 0.2	3)					
13.1.2 NRCT								
Ammori 2020	7	9	14	18	0.5%	1.00 [0.15, 6.85]		
Asbun 2012	37	39		141	0.7%	3.79 [0.86, 16.82]		
Chen K 2021	94	101	90		1.6%	1.64 [0.61, 4.42]		
Choi 2020	25		24	34	0.4%	5.21 [1.03, 26.27]		_
Conrad 2017	35		21	25	0.8%	1.33 [0.32, 5.53]		
Croome 2014	84		164		6.2%	1.07 [0.61, 1.86]		
Dang C 2021	110			131	4.5%	0.94 [0.48, 1.84]		
Delitto 2016	47	52	37	50	0.9%	3.30 [1.08, 10.10]		
Dokmak 2015	29		29	36	1.4%	1.00 [0.31, 3.21]		
El Nakeeb 2020	32		62	74	1.4%	1.24 [0.40, 3.82]		
Han SH 2020	100			113	1.0%	0.22 [0.02, 2.03]		
Kantor 2017	651	828		7385	61.6%	1.15 [0.97, 1.37]	_	
Khaled 2018	13		11	15	0.4%	2.36 [0.36, 15.45]		
Kuesters 2018	54	62	195		2.3%	2.87 [1.31, 6.30]		
Mazzola 2021	38		38	50	2.3%	1.00 [0.40, 2.50]		
Mendoza 2015	15		29	34	0.9%	0.86 [0.18, 4.11]		
Senthilnathan 2015		45	108		1.3%	0.95 [0.28, 3.20]		
Shin 2019	44	49	47	50	1.2%	0.56 [0.13, 2.49]		
Stauffer 2016	49		154		2.8%	1.38 [0.62, 3.05]		
Tan JKH 2019	19		16	20	0.2%	4.75 [0.48, 46.91]		
Yoo 2020	68		68	69	0.3%	1.00 [0.06, 16.32]		
Zhang Z 2022	39		40	47	1.7%	0.85 [0.28, 2.58]		
Zhou W 2019	55		88	93		6.90 [0.37, 127.19]		
Subtotal (95% CI)		2000		9289	94.7%	1.24 [1.08, 1.42]	•	
Total events	1686		7198					
Heterogeneity: Chi ²				l² = 1 %				
Test for overall effec	et: Z = 3.03	(P = 0.0	02)					
Total (95% CI)		2411		9696	100.0%	1.25 [1.09, 1.43]	•	
Total events	2067		7568					
Heterogeneity: Chi ²		= 26 (P		I² = 0%			⊢ − − + − − +	
Test for overall effect				/0			0.01 0.1 i 10	10
Test for subaroup d				1 /0 - 1	0.000 18-	004	Favours OPD Favours LPD	

Forest plot of comparison between LPD and OPD on R0 resection. LPD, laparoscopic pancreaticoduodenectom; OPD, open pancreaticoduodenectomy

these results should be interpreted with caution. Surgeons might be more conservative and discreet to choose LPD for malignancy because lymphadenectomy and negative margin are indispensable for radical cure and can be more challenging during laparoscopic surgery; therefore, healthier patients with earlier tumor stage may have been chosen for LPD especially in the initial stage of performing LPD (34, 44, 48, 64, 79). The lower intraoperative blood transfusion rate became not significant in LPD when studies analyzed all malignancies, which could be attributed to the increased complexity of radical resection by the laparoscopic approach. As LPD for malignancy might attenuate the effect of lower blood loss and transfusion, surgical indication selection for LPD should be considered and explored in future studies.

The lower overall postoperative complications and intraoperative blood transfusion for LPD became not significant in the subgroup analysis of studies with no more than 50 LPD cases. Although the operative time was still longer for LPD than the open procedure, the subgroup analysis of studies with more than 50 LPD cases demonstrated a significant reduction of operative time in LPD compared to studies with no more than 50 LPD cases. Given the detection power of sample size, some studied outcomes such as postoperative morbidity, intraoperative blood transfusion, and operative time may also have been influenced by sample size issues (4, 14, 80). Although all RCTs explicitly described their calculation method for ascertaining sample size, the ascertained sample sizes had great discrepancy. The RCTs of Palanivelu et al. (35) and Poves et al. (36) calculated the sample size according to the primary outcome of hospital stay and indicated that only 32 patients were required in each group. However, Wang et al. (38) also calculated hospital stay and assessed that the minimum number of patients required in each group was 274. Furthermore, the RCT of van Hilst et al. (37) calculated a sample size of 68 patients for each group according to the time of postoperative functional recovery but was prematurely terminated with only 50 LPD cases. It was suggested that some of the current studies may be underpowered for comparing complex surgical procedures, and further trials with larger numbers of patients are indispensable to clarify surgical outcomes between LPD and OPD with adequate statistical power.

The improved overall postoperative complications and hospital stay were influenced by studies of baseline matching incomplete in subgroup analysis. We think outcomes such as hospital stay and overall complications are susceptible to bias, where comparable baseline characteristics and standard definitions are important for accurate comparison of surgical procedures. In addition, our analyses showed that serious postoperative complications were not reduced in the LPD group. Because the laparoscopic technique is less invasive, LPD might mainly decrease medical and minor surgical complications. This is not surprising because the reduced medical and minor surgical complications of the laparoscopic technique also could help to reduce hospital stay (27, 81). However, a more detailed analysis of postoperative complications was not performed due to lack of information. LPD could provide benefits in reducing medical and minor surgical complications and hospital stay; further studies designed to validate this phenomenon should match completely, unify perioperative management, and use standard outcome definition.

There were several limitations in this study. Significant heterogeneity was shown in some outcomes, which might be explained by differences in study design, sample size, surgeons' proficiency, baseline characteristics, healthcare system, postoperative recovery protocol, and other factors. Variations in sample size among studies were large, and some studies enrolled patients during a wide study period, which may have introduced biases due to the advancement in mastering surgical skills and improvement in surgical instruments. Pilot studies that might be more prone to choose LPD for benign or low-grade malignant patients may also have introduced biases. All of the factors above might make the surgical results more susceptible to the methodological quality of clinical trials and lead to high heterogeneity among studies. The economical results and longterm oncologic outcomes are not evaluated in our study, as adequate data are missing at present. With the technological advances of computer vision and artificial intelligence playing a role in the improvement of LPD, whether these theoretical advantages could translate into improved patient outcomes, especially for a more complex condition such as malignancy, needs further studies (82, 83).

In conclusion, the results of our meta-analysis suggest that LPD is associated with non-inferior short-term surgical outcomes and oncologic adequacy compared to OPD when performed by experienced surgeons at high-volume centers. LPD may result in reduced overall postoperative morbidity, blood loss, intraoperative transfusion, and DGE, but prolonged operative time. In addition, recent studies have addressed the issue of surgical safety of LPD but may not have been sufficiently powered to evaluate the differences in postoperative complications between LPD and OPD. Further RCTs are required to investigate whether there are advantages of LPD for the management of pancreatic and periampullary tumors.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

Data acquisition: YY, YH, and YS. Manuscript drafting: YY, YH, and YS. Statistical analysis: YY, CC, and XZ. Manuscript revision: BW and YS. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by Guangdong Basic and Applied Basic Research Foundation (2021A1515011261).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations,

References

1. Farges O, Bendersky N, Truant S, Delpero JR, Pruvot FR, Sauvanet A, et al. The theory and practice of pancreatic surgery in France. *Ann Surg* (2017) 266:797-804. doi: 10.1097/SLA.00000000002399

2. Balzano G, Guarneri G, Pecorelli N, Paiella S, Rancoita PMV, Bassi C, et al. Modelling centralization of pancreatic surgery in a nationwide analysis. *Br J Surg* (2020) 107:1510–9. doi: 10.1002/bjs.11716

3. Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. *Nat Rev Clin Oncol* (2019) 16:11–26. doi: 10.1038/s41571-018-0112-1

4. Polonski A, Izbicki JR, Uzunoglu FG. Centralization of pancreatic surgery in Europe. J Gastrointest Surg (2019) 23:2081–92. doi: 10.1007/s11605-019-04215-y

5. Di Saverio S, Podda M, De Simone B, Ceresoli M, Augustin G, Gori A, et al. Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines. *World J Emerg Surg* (2020) 15:27. doi: 10.1186/s13017-020-00306-3

6. Wakabayashi G, Iwashita Y, Hibi T, Takada T, Strasberg SM, Asbun HJ, et al. Tokyo Guidelines 2018: surgical management of acute cholecystitis: safe steps in laparoscopic cholecystectomy for acute cholecystitis (with videos). *J Hepatobil Pancreat Sci* (2018) 25:73–86. doi: 10.1002/jhbp.517

7. Japanese Gastric Cancer AssociationJapanese Gastric cancer treatment guidelines 2018 (5th edition). *Gastric Cancer* (2021) 24:1–21. doi: 10.1007/s10120-020-01042-y

8. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. *Int J Clin Oncol* (2018) 23:1–34. doi: 10.1007/s10147-017-1101-6

 Acuna SA, Chesney TR, Ramjist JK, Shah PS, Kennedy ED, Baxter NN. Laparoscopic versus open resection for rectal cancer: A noninferiority meta-analysis of quality of surgical resection outcomes. *Ann Surg* (2019) 269:849–55. doi: 10.1097/ SLA.000000000003072

10. Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc (1994) 8:408–10. doi: 10.1007/BF00642443

11. Coppola A, Stauffer JA, Asbun HJ. Laparoscopic pancreatoduodenectomy: current status and future directions. *Updates Surg* (2016) 68:217–24. doi: 10.1007/s13304-016-0402-z

12. Maher H, Jin W, Mou Y, Davies H. The prospective of laparoscopic pancreaticoduodenectomy for cancer management. *Chin Clin Oncol* (2017) 6:8. doi: 10.21037/cco.2017.01.03

13. Strobel O, Büchler MW. Laparoscopic pancreatoduodenectomy: safety concerns and no benefits. *Lancet Gastroenterol Hepatol* (2019) 4:186–7. doi: 10.1016/S2468-1253 (19)30006-8

14. Nickel F, Haney CM, Kowalewski KF, Probst P, Limen EF, Kalkum E, et al. Laparoscopic versus open pancreaticoduodenectomy: A systematic review and metaanalysis of randomized controlled trials. *Ann Surg* (2020) 271:54–66. doi: 10.1097/ SLA.000000000003309

15. Ausania F, Landi F, Martínez-Pérez A, Fondevila C. A meta-analysis of randomized controlled trials comparing laparoscopic vs open pancreaticoduodenectomy. *HPB (Oxford)* (2019) 21:1613–20. doi: 10.1016/j.hpb.2019.05.017

16. Lin D, Yu Z, Chen X, Chen W, Zou Y, Hu J, et al. Laparoscopic versus open pancreatoduodenectomy: a meta-analysis of randomized controlled trials. *Rev Esp Enferm Dig* (2020) 112(1):34–40. doi: 10.17235/reed.2019.6343/2019

17. Sun R, Yu J, Zhang Y, Liang Z, Han X. Perioperative and oncological outcomes following minimally invasive versus open pancreaticoduodenectomy for pancreatic duct adenocarcinoma. *Surg Endosc* (2021) 35:2273–85. doi: 10.1007/s00464-020-07641-1

18. Chen K, Zhou Y, Jin W, Zhu Q, Lu C, Niu N, et al. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. *Surg Endosc* (2020) 34:1948–58. doi: 10.1007/s00464-019-06968-8

19. Feng Q, Liao W, Xin Z, Jin H, Du J, Cai Y, et al. Laparoscopic pancreaticoduodenectomy versus conventional open approach for patients with

or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.1093395/ full#supplementary-material

pancreatic duct adenocarcinoma: An up-to-Date systematic review and meta-analysis. Front Oncol (2021) 11:749140. doi: 10.3389/fonc.2021.749140

20. Kamarajah SK, Bundred JR, Marc OS, Jiao LR, Hilal MA, Manas DM, et al. A systematic review and network meta-analysis of different surgical approaches for pancreaticoduodenectomy. *HPB (Oxford)* (2020) 22:329-39. doi: 10.1016/j.hpb.2019.09.016

21. Aiolfi A, Lombardo F, Bonitta G, Danelli P, Bona D. Systematic review and updated network meta-analysis comparing open, laparoscopic, and robotic pancreaticoduodenectomy. *Updates Surg* (2021) 73:909–22. doi: 10.1007/s13304-020-00916-1

22. Abraham NS, Byrne CJ, Young JM, Solomon MJ. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. *J Clin Epidemiol* (2010) 63:238–45. doi: 10.1016/j.jclinepi.2009.04.005

23. Higgins JPT, Thomas J, Chandler J, Chandler J, Welch VA, Higgins JP. *Cochrane handbook for systematic reviews of interventions. 2nd Edition*. Chichester (UK: John Wiley & Sons (2019).

24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *Bmj* (2009) 339:b2700. doi: 10.1136/bmj.b2700

25. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *Bmj* (2011) 343:d5928. doi: 10.1136/bmj.d5928

26. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg* (2003) 73:712-6. doi: 10.1046/j.1445-2197.2003.02748.x

27. Viñuela EF, Gonen M, Brennan MF, Coit DG, Strong VE. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. *Ann Surg* (2012) 255:446–56. doi: 10.1097/SLA.0b013e31824682f4

28. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* (2005) 5:13. doi: 10.1186/1471-2288-5-13

29. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* (2014) 14:135. doi: 10.1186/1471-2288-14-135

30. Chapman BC, Gajdos C, Hosokawa P, Henderson W, Paniccia A, Overbey DM, et al. Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. *Surg Endosc* (2018) 32:2239–48. doi: 10.1007/s00464-017-5915-0

31. Sharpe SM, Talamonti MS, Wang CE, Prinz RA, Roggin KK, Bentrem DJ, et al. Early national experience with laparoscopic pancreaticoduodenectomy for ductal adenocarcinoma: A comparison of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy from the national cancer data base. *J Am Coll Surg* (2015) 221:175–84. doi: 10.1016/j.jamcollsurg.2015.04.021

32. Kantor O, Talamonti MS, Sharpe S, Lutfi W, Winchester DJ, Roggin KK, et al. Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. *Am J Surg* (2017) 213:512–5. doi: 10.1016/j.amjsurg. 2016.10.030

33. Zimmerman AM, Roye DG, Charpentier KP. A comparison of outcomes between open, laparoscopic and robotic pancreaticoduodenectomy. *HPB (Oxford)* (2018) 20:364–9. doi: 10.1016/j.hpb.2017.10.008

34. Xourafas D, Pawlik TM, Cloyd JM. Independent predictors of increased operative time and hospital length of stay are consistent across different surgical approaches to pancreatoduodenectomy. *J Gastrointest Surg* (2018) 22:1911–9. doi: 10.1007/s11605-018-3834-6

35. Palanivelu C, Senthilnathan P, Sabnis SC, Babu NS, Srivatsan Gurumurthy S, Anand Vijai N, et al. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. *Br J Surg* (2017) 104:1443–50. doi: 10.1002/bjs.10662

36. Poves I, Burdío F, Morató O, Iglesias M, Radosevic A, Ilzarbe L, et al. Comparison of perioperative outcomes between laparoscopic and open approach for pancreatoduodenectomy: The PADULAP randomized controlled trial. *Ann Surg* (2018) 268:731-9. doi: 10.1097/SLA.00000000002893

37. van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. *Lancet Gastroenterol Hepatol* (2019) 4:199–207. doi: 10.1016/S2468-1253(19) 30004-4

38. Wang M, Li D, Chen R, Huang X, Li J, Liu Y, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, openlabel, randomised controlled trial. *Lancet Gastroenterol Hepatol* (2021) 6:438-47. doi: 10.1016/S2468-1253(21)00054-6

39. Ammori BJ, Omari B, Al Najjar H, Abdullah N, Dabous A, Daoud F, et al. A casematched comparative study of laparoscopic versus open pancreaticoduodenectomy. *Surg Laparosc Endosc Percutan Tech* (2020) 30:276–80. doi: 10.1097/SLE.000000000000777

40. Asbun HJ, Stauffer JA. Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and severity of complications using the accordion severity grading system. *J Am Coll Surg* (2012) 215:810–9. doi: 10.1016/j.jamcollsurg.2012.08.006

41. Chen K, Pan Y, Huang CJ, Chen QL, Zhang RC, Zhang MZ, et al. Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy. *BMC Cancer* (2021) 21:382. doi: 10.1186/s12885-021-08117-8

42. Chen XM, Sun DL, Zhang Y. Laparoscopic versus open pancreaticoduodenectomy combined with uncinated process approach: A comparative study evaluating perioperative outcomes (Retrospective cohort study). *Int J Surg* (2018) 51:170–3. doi: 10.1016/j.ijsu.2018.01.038

43. Choi M, Hwang HK, Rho SY, Lee WJ, Kang CM. Comparing laparoscopic and open pancreaticoduodenectomy in patients with pancreatic head cancer: oncologic outcomes and inflammatory scores. *J Hepatobil Pancreat Sci* (2020) 27:124–31. doi: 10.1002/jhbp.697

44. Chopinet S, Fuks D, Rinaudo M, Massol J, Gregoire E, Lamer C, et al. Postoperative bleeding after laparoscopic pancreaticoduodenectomy: the achilles' heel? *World J Surg* (2018) 42:1138–46. doi: 10.1007/s00268-017-4269-z

45. Conrad C, Basso V, Passot G, Zorzi D, Li L, Chen HC, et al. Comparable long-term oncologic outcomes of laparoscopic versus open pancreaticoduodenectomy for adenocarcinoma: a propensity score weighting analysis. *Surg Endosc* (2017) 31:3970–8. doi: 10.1007/s00464-017-5430-3

46. Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? *Ann Surg* (2014) 260:633–638; discussion 638-640. doi: 10.1097/SLA.00000000000037

47. Dang C, Wang M, Zhu F, Qin T, Qin R. Comparison of laparoscopic and open pancreaticoduodenectomy for the treatment of nonpancreatic periampullary adenocarcinomas: a propensity score matching analysis. *Am J Surg* (2021) 222:377–82. doi: 10.1016/j.amjsurg.2020.12.023

48. Delitto D, Luckhurst CM, Black BS, Beck JL, George TJ Jr, Sarosi GA, et al. Oncologic and perioperative outcomes following selective application of laparoscopic pancreaticoduodenectomy for periampullary malignancies. *J Gastrointest Surg* (2016) 20:1343–9. doi: 10.1007/s11605-016-3136-9

49. Ding W, Wu W, Tan Y, Chen X, Duan Y, Sun D, et al. The comparation of short-term outcome between laparoscopic and open pancreaticoduodenectomy: a propensity score matching analysis. *Updates Surg* (2021) 73:419–27. doi: 10.1007/s13304-021-00997-6

50. Dokmak S, Ftériche FS, Aussilhou B, Bensafta Y, Lévy P, Ruszniewski P, et al. Laparoscopic pancreaticoduodenectomy should not be routine for resection of periampullary tumors. *J Am Coll Surg* (2015) 220:831–8. doi: 10.1016/j.jamcollsurg. 2014.12.052

51. El Nakeeb A, Attia M, El Sorogy M, Ezzat H, Shehta A, Salem A, et al. Laparoscopic pancreaticodudenectomy for periampullary tumor: Should it be a routine? a propensity score-matched study. *Surg Laparosc Endosc Percutan Tech* (2020) 30:7–13. doi: 10.1097/SLE.000000000000715

52. Han SH, Kang CM, Hwang HK, Yoon DS, Lee WJ. The yonsei experience of 104 laparoscopic pancreaticoduodenectomies: a propensity score-matched analysis with open pancreaticoduodenectomy. *Surg Endosc* (2020) 34:1658–64. doi: 10.1007/s00464-019-06942-4

53. Katsuki R, Jo T, Yasunaga H, Kumazawa R, Uda K. Outcomes of laparoscopic versus open pancreatoduodenectomy: A nationwide retrospective cohort study. *Surgery* (2021) 169:1427–33. doi: 10.1016/j.surg.2020.12.018

54. Khaled YS, Fatania K, Barrie J, De Liguori N, Deshpande R, O'Reilly DA, et al. Matched case-control comparative study of laparoscopic versus open pancreaticoduodenectomy for malignant lesions. *Surg Laparosc Endosc Percutan Tech* (2018) 28:47–51. doi: 10.1097/SLE.00000000000381

55. Kuesters S, Chikhladze S, Makowiec F, Sick O, Fichtner-Feigl S, Hopt UT, et al. Oncological outcome of laparoscopically assisted pancreatoduodenectomy for ductal adenocarcinoma in a retrospective cohort study. *Int J Surg* (2018) 55:162–6. doi: 10.1016/j.ijsu.2018.05.026

56. Lee CS, Kim EY, You YK, Hong TH. Perioperative outcomes of laparoscopic pancreaticoduodenectomy for benign and borderline malignant periampullary disease compared to open pancreaticoduodenectomy. *Langenbecks Arch Surg* (2018) 403:591–7. doi: 10.1007/s00423-018-1691-0

57. Mazzola M, Giani A, Crippa J, Morini L, Zironda A, Bertoglio CL, et al. Totally laparoscopic versus open pancreaticoduodenectomy: A propensity score matching analysis of short-term outcomes. *Eur J Surg Oncol* (2021) 47:674–80. doi: 10.1016/ j.ejso.2020.10.036

58. Mendoza AS3rd, Han HS, Yoon YS, Cho JY, Choi Y, et al. Laparoscopy-assisted pancreaticoduodenectomy as minimally invasive surgery for periampullary tumors: a comparison of short-term clinical outcomes of laparoscopy-assisted pancreaticoduodenectomy and open pancreaticoduodenectomy. *J Hepatobil Pancreat Sci* (2015) 22:819–24. doi: 10.1002/jhbp.289

59. Meng LW, Cai YQ, Li YB, Cai H, Peng B. Comparison of laparoscopic and open pancreaticoduodenectomy for the treatment of nonpancreatic periampullary adenocarcinomas. *Surg Laparosc Endosc Percutan Tech* (2018) 28:56–61. doi: 10.1097/SLE.0000000000000504

60. Mesleh MG, Stauffer JA, Bowers SP, Asbun HJ. Cost analysis of open and laparoscopic pancreaticoduodenectomy: a single institution comparison. *Surg Endosc* (2013) 27:4518–23. doi: 10.1007/s00464-013-3101-6

61. Senthilnathan P, Chinnusamy P, Ramanujam A, Sivakumar SG, Natesan AV, Chandramaliteeswaran C, et al. Comparison of pathological radicality between open and laparoscopic pancreaticoduodenectomy in a tertiary centre. *Indian J Surg Oncol* (2015) 6:20–5. doi: 10.1007/s13193-014-0372-x

62. Shin H, Song KB, Kim YI. Propensity score-matching analysis comparing laparoscopic and open pancreaticoduodenectomy in elderly patients. *Sci Rep* (2019) 9 (1):12961. doi: 10.1038/s41598-019-49455-9

63. Song KB, Kim SC, Hwang DW, Lee JH, Lee DJ, Lee JW, et al. Matched case-control analysis comparing laparoscopic and open pylorus-preserving pancreaticoduodenectomy in patients with periampullary tumors. *Ann Surg* (2015) 262:146–55. doi: 10.1097/SLA.00000000001079

64. Stauffer JA, Coppola A, Mody K, Asbun HJ. Laparoscopic versus open distal pancreatectomy for pancreatic adenocarcinoma. *World J Surg* (2016) 40:1477–84. doi: 10.1007/s00268-016-3412-6

65. Tan CL, Zhang H, Peng B, Li KZ. Outcome and costs of laparoscopic pancreaticoduodenectomy during the initial learning curve vs laparotomy. *World J Gastroenterol* (2015) 21:5311–9. doi: 10.3748/wjg.v21.i17.5311

66. Tan JKH, Ng JJ, Yeo M, Koh FHX, Bonney GK, Ganpathi IS, et al. Propensity score-matched analysis of early outcomes after laparoscopic-assisted versus open pancreaticoduodenectomy. *ANZ J Surg* (2019) 89:E190–e194. doi: 10.1111/ans.15124

67. Tee MC, Croome KP, Shubert CR, Farnell MB, Truty MJ, Que FG, et al. Laparoscopic pancreatoduodenectomy does not completely mitigate increased perioperative risks in elderly patients. *HPB (Oxford)* (2015) 17:909–18. doi: 10.1111/hpb.12456

68. Tran TB, Dua MM, Worhunsky DJ, Poultsides GA, Norton JA, Visser BC. The first decade of laparoscopic pancreaticoduodenectomy in the united states: Costs and outcomes using the nationwide inpatient sample. *Surg Endosc* (2016) 30:1778–83. doi: 10.1007/s00464-015-4444-y

69. Yoo D, Song KB. A comparative study of laparoscopic versus open pancreaticoduodenectomy for ampulla of vater carcinoma. *J Clin Med* (2020) 9:. doi: 10.3390/jcm9072214

70. Zhang Z, Yin T, Qin T, Pan S, Wang M, Zhang H, et al. Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarcinoma: A propensity score-matching analysis of long-term survival. *Pancreatology* (2022) 22:317–24. doi: 10.1016/j.pan.2021.12.005

71. Zhou W, Jin W, Wang D, Lu C, Xu X, Zhang R, et al. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. *Cancer Commun (Lond)* (2019) 39:66. doi: 10.1186/s40880-019-0410-8

72. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery* (2005) 138:8–13. doi: 10.1016/j.surg.2005.05.001

73. Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH): an international study group of pancreatic surgery (ISGPS) definition. *Surgery* (2007) 142:20–5. doi: 10.1016/j.surg.2007.02.001

74. Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the international study group of liver surgery. *Surgery* (2011) 149:680–8. doi: 10.1016/j.surg.2010.12.002

75. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the international study group of pancreatic surgery (ISGPS). *Surgery* (2007) 142:761–8. doi: 10.1016/j.surg.2007.05.005

76. Panwar R, Pal S. The international study group of pancreatic surgery definition of delayed gastric emptying and the effects of various surgical modifications on the occurrence of delayed gastric emptying after pancreatoduodenectomy. *Hepatobil Pancreat Dis Int* (2017) 16:353–63. doi: 10.1016/S1499-3872(17)60037-7

77. Li X, Qin T, Zhu F, Wang M, Dang C, He L, et al. Clinical efficacy of the preservation of the hepatic branch of the vagus nerve on delayed gastric emptying after laparoscopic pancreaticoduodenectomy. *J Gastrointest Surg* (2021) 25:2172–83. doi: 10.1007/s11605-021-05024-y

78. Chan KS, Wang ZK, Syn N, Goh BKP. Learning curve of laparoscopic and robotic pancreas resections: a systematic review. *Surgery* (2021) 170:194–206. doi: 10.1016/j.surg.2020.11.046

79. Umemura A, Nitta H, Takahara T, Hasegawa Y, Sasaki A. Current status of laparoscopic pancreaticoduodenectomy and pancreatectomy. *Asian J Surg* (2018) 41:106–14. doi: 10.1016/j.asjsur.2016.09.003

80. Lidsky ME, Sun Z, Nussbaum DP, Adam MA, Speicher PJ, Blazer DG 3rd, et al. Going the extra mile: Improved survival for pancreatic cancer patients traveling to high-volume centers. *Ann Surg* (2017) 266:333–8. doi: 10.1097/SLA.000000000001924

81. Chen X, Feng X, Wang M, Yao X. Laparoscopic versus open distal gastrectomy for advanced gastric cancer: A meta-analysis of randomized controlled trials and high-quality

nonrandomized comparative studies. *Eur J Surg Oncol* (2020) 46:1998–2010. doi: 10.1016/ j.ejso.2020.06.046

82. Gumbs AA, Chouillard E, Abu Hilal M, Croner R, Gayet B, Gagner M. The experience of the minimally invasive (MI) fellowship-trained (FT) hepatic-pancreatic and biliary (HPB) surgeon: could the outcome of MI pancreatoduodenectomy for periampullary tumors be better than open? *Surg Endosc* (2021) 35(9):5256–67. doi: 10.1007/s00464-020-08118-x

83. Taher H, Grasso V, Tawfik S, Gumbs A. The challenges of deep learning in artificial intelligence and autonomous actions in surgery: a literature review. *Art Int Surg* (2022) 2:144–58. doi: 10.20517/ais.2022.11